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Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that is characterized 
by immune-mediated destruction of small and medium intrahepatic bile ducts that manifests 
as cholestasis. Like other autoimmune diseases, it has a female predominance, co-exists with 
other autoimmune diseases, and presents with disease-specific autoantibodies. It has a slowly 
progressive course over many years that can result in ductopenia, leading to fibrosis and 
cirrhosis, and premature death in the absence of liver transplantation. Ursodeoxycholic acid 
(UDCA) has been the only therapeutic option for patients until recently, when obeticholic acid 
(OCA) received accelerated approval as a second-line therapy in patients who do not respond 
to UDCA or who lack tolerance for it.  
Epidemiology   
The predominant population affected by PBC are middle-aged women, with an estimated 1 in 
1,000 women over the age of 40 affected globally.1 The specific female: male ratios reported 
in the literature vary by study and region with a mean proportion of female patients of 92% that 
ranges from 76 to 100%.2 The incidence of PBC is not limited to any particular ethnic group or 
geographical region and affects people from all geographical regions. However, reports on the 
incidence and prevalence differ according to region, with increased prevalence in Caucasian 
populations, particularly from Northern Europe.3,4 Accordingly, the prevalence of PBC has 
been shown to be variable according to age, sex, and race in the United States (US), as 
demonstrated in a study from the Fibrotic Liver Disease (FOLD) Consortium that reports the 
highest prevalence in women, White patients, and patients aged 60-70 years.5 A review on the 
epidemiology of PBC that included predominantly North American and European studies 
reported that the annual incidence and prevalence rates per 100,000 individuals ranged from 
0.33-5.8 and 1.91-40.2, respectively.2 While varying rates of incidence and prevalence 
according to region can be a result of differences in environmental factors, they may also reflect 
genetics and ethnicity. The prevalence of PBC is reportedly increasing over the years.2,6 
Temporal trends in the incidence of PBC have discrepancies, as some studies report stability 
while others report increases.6–8  
There are several plausible explanations for the rise in prevalence and incidence rates for 
PBC. The increase may be a consequence of improved case ascertainment methods or 
increased routine testing for liver biochemistry and antimitochondrial antibody (AMA)-positivity 
driven by increased disease awareness, suggesting an underestimation in earlier studies.9 
Further, a true increase in prevalence can be a result of an increase in survival of PBC patients 
due to prompt diagnosis and enhanced care. However, one cannot exclude the possibility that 
environmental or behavioural changes over time may lead to increased exposure to an 
environmental agent that triggers the disease.9   
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Etiology: Genetics and Environment 
Although the specific cause of PBC is unknown, there is consensus that it is likely triggered by 
a complex interaction between genetic and environmental factors. The role of genetics has 
been demonstrated in familial and genetic association studies. A high concordance rate of 63% 
(5 out of 8) for PBC has been reported in monozygotic twins.10 Further, PBC occurs in 4-9% 
of family members of patients with PBC, higher than the general population.11–14 Even in the 
absence of disease, first-degree relative of patients with PBC have increased AMA-positivity 
compared to age- and sex-matched controls, with positivity in 7-19% and 0-1%, 
respectively.12,14,15  
Initially, genetic studies in PBC relied on biologically plausible genes and those selected based 
on associations with other autoimmune diseases.16 From these studies, the primary genes 
implicated in PBC were the human leukocyte antigen (HLA) genes in the major 
histocompatibility complex (MHC) region, which are responsible for antigen presentation. In 
European and North American populations, consistent associations have been identified for 
HLA DRB1*0801.17–19 In Japanese populations, associations have been identified for HLA 
DRB*13.20 Genome-wide association studies have increased our ability to detect genetic 
variants common in a population by assessing millions of single nucleotide polymorphisms 
(SNP), resulting in the identification of additional PBC-associated HLA variants at the DRB1, 
DQA1, and DQB1 loci, as well as non-HLA loci.16 
Supporting evidence for a critical role of environmental factors in the development of PBC is 
the documentation of spatial clustering of PBC cases in Northeast England and Alaska, as well 
as near toxic waste sites and among atomic bomb survivors from Hiroshima.8,21–24 Research 
into an environmental trigger for PBC has not documented a strong correlation to any particular 
factor. However, there have been associations with recurrent urinary tract infections, 
active/past smoking, use of hormone replacement therapy, frequent use of nail polish, and hair 
dye.13,25–28 Infectious agents have also been implicated, including Escherichia coli (E. coli), 
mycobacteria, Novosphingobium aromaticivorans, Lactobacillus, Helicobacter pylori, human 
retrovirus, mouse mammary tumour virus, and Chlamydia pneumoniae.27,29  
Clinical Presentation and Symptoms 
Like other autoimmune diseases, patients with PBC present with increased rates of co-existing 
autoimmune diseases that include Sjogrens/sicca syndrome, complete or incomplete CREST 
syndrome, rheumatoid arthritis, and thyroid disorders, of which the most common one is 
Sjogrens/sicca syndrome.25,30–32  
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There is variability in the type and severity of symptoms experienced by patients at diagnosis, 
although the proportion of patients presenting without symptoms has reportedly increased over 
the years.33,34 Although an absence of symptoms generally suggests that patients are also 
presenting at an earlier disease stage, it is not always the case, as some have died before the 
development of symptoms.35 In symptomatic patients, some common symptoms include 
fatigue, pruritus, jaundice, pain in the upper right quadrant, hyperlipidemia, keratoconjunctivitis, 
steatorrhea, and xerostomia.32 Of these, the most commonly experienced symptoms are 
pruritus and fatigue35, although still variable in prevalence and severity, since younger patients 
are more prone to fatigue and pruritus and non-Caucasians are more likely to have more 
severe pruritus.36,37 The presence of these symptoms, particularly fatigue, imposes a great 
impact on quality of life even though it does not correlate with disease severity.38–40 This 
emphasizes the importance of recognizing and managing health-related quality of life 
(HRQOL), which can be defined as ‘patients’ perceptions of their health status, reflecting how 
they feel and how much their disease affects their way of life’ and is commonly measured by 
the PBC-40 questionnaire.41,42 This questionnaire was specifically developed for PBC and 
measures six domains implicated in quality of life: fatigue, emotional, social, cognitive function, 
general symptoms, and itch.42  
In early studies of untreated or largely untreated patients, the majority of asymptomatic patients 
would develop symptoms as the disease progressed.43,44 One study reported 50% and 95% of 
patients developed symptoms after 5 and 20 years, respectively.43 In a Japanese cohort of 
asymptomatic UDCA-treated patients with a mean follow-up of 5.2 years, only 15% of patients 
developed liver-related symptoms, in which biochemical response defined as normalization of 
gamma-glutamyl transpeptidase (GGT) or a reduction ≥70% at 6 months was associated with 
a decreased risk for symptom development.45   
Diagnosis of PBC 
The diagnosis of PBC is made when a patient fulfills two of the following criteria: i) biochemical 
evidence of cholestasis with an elevation in ALP for at least 6 months; ii) AMA titers above 
1:40; iii) a liver biopsy with evidence of non-suppurative cholangitis and destruction of 
small/medium-sized bile ducts.1 Diagnosis is mainly based on cholestatic liver biochemistry 
and AMA, as liver biopsies are less frequent nowadays, except when a patient lacks 
autoantibodies or doesn’t demonstrate biochemical abnormalities.46 In AMA-negative patients, 
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Biochemical, serological, and histological features of PBC 
Liver biochemistry   
Early biochemical markers of cholestasis include elevations in ALP and GGT, supporting the 
inclusion of ALP in diagnostic criteria. Elevations in GGT can confirm the hepatic origin of ALP 
elevation and can usually be detected prior to elevations in ALP.1 The magnitude of elevation 
of ALP is correlated with severity of ductopenia and inflammation, as well disease 
progression.1,48 Patients can also demonstrate mild elevations in transaminases (ALT and 
AST) and elevations of immunoglobulins, primarily IgM. Elevations of transaminases reflects 
the extent of liver parenchyma inflammation and necrosis.1,48 Later in the course of PBC, 
increases in conjugated bilirubin, alterations in prothrombin time, and decreases in serum 
albumin are observed. Hyperbilirubinemia reflects the severity of ductopenia and biliary 
piecemeal necrosis.48  
Serology  
The serologic hallmark for PBC is AMA given its presence in 90-95% of patients. There is no 
difference in biochemical, histological, and clinical features at presentation or response to 
treatment between AMA- positive and -negative patients.49,50 The autoantigens of AMA 
correspond to the family of 2-oxo acid dehydrogenase complexes, termed M2, that are 
localized to the inner mitochondrial membrane.51,52 This family of homologous enzyme 
complexes includes pyruvate dehydrogenase complex, branched-chain oxo acid 
dehydrogenase complex, and oxoglutarate dehydrogenase complex.51 The main autoantigen 
of AMA is the E2 subunit of 2-oxo acid dehydrogenase complexes, for which 80-90% of sera 
react to E2 from pyruvate dehydrogenase, specifically its lipoic acid binding site 
(autoepitope).53 Historically, the detection of AMA antibodies was predominantly performed 
with indirect immunofluorescence, however there has been a shift towards methods that 
provide greater sensitivity and specificity, as well as greater speed and automation, such as 
enzyme-linked immunosorbent assay (ELISA) and western immunoblots.54,55  
Antinuclear antibodies are another class of autoantibodies that can be found in the context of 
PBC. They demonstrate high specificity for PBC (99%) and can be detected in 50-70% of 
patients.47,56 ANAs are more frequently observed in AMA-negative patients.49 The nuclear 
envelope contains the autoantigen for ANA, which yields multiple nuclear dot (ex. anti-sp100) 
or Rim-like/membranous patterns (ex. anti-gp210) by indirect immunofluorescence.47  
 




Histologically, PBC is characterized by chronic non-suppurative inflammation of the portal sites 
and immune-mediated destruction of bile ducts. Although a liver biopsy is no longer essential 
for a diagnosis of PBC and sparely carried out due to its invasive nature, it can aid in staging 
of the disease. There are four histologic stages, which are mainly staged with Ludwig or 
Scheuer systems. According to Scheuer system, Stage I is defined by portal hepatitis with duct 
lesions (florid duct lesion), stage II is defined by periportal hepatitis with ductular proliferation, 
stage III is defined by septal fibrosis, and stage IV is defined by cirrhosis.57 According to Ludwig 
staging, Stage I is defined by portal hepatitis, stage II is defined by periportal hepatitis, Stage 
III is defined by bridging necrosis or septal fibrosis or both, and Stage IV is defined by 
cirrhosis.58 In the absence of therapy, a patient progresses histologically within 2 years, with 
progression rates of 62% for stage I/II and 50% for stage III.59  
Since liver biopsies are invasive, there have been efforts to develop non-invasive methods to 
assess fibrosis. Non-invasive biochemical markers include AST/ALT ratio, AST to platelet ratio 
index (APRI), FIB-4, and ELF test. A promising non-invasive method of assessing liver fibrosis 
is transient elastography, which measures liver stiffness and has demonstrated high 
correlations with histologic fibrosis stage in PBC, with an AUROC of 0.89 for F>2 and 0.96 for 
F=4.60 
Loss of self-tolerance  
The trigger for loss of self-tolerance and the mechanism by which PDC-E2 becomes antigenic 
is not fully understood. There are various plausible mechanisms: molecular mimicry, self-
alteration of PDC-E2 by xenobiotics, and the apoptotic mechanism of biliary epithelial cells that 
releases intact immunogenic epitopes.14,61 There is experimental evidence for molecular 
mimicry between a self-antigen and an exogenous bacterial/virologic antigen for PDC-E2, as 
cross-reactivity was detected between human PDC-E2 and bacterial E2 from E. coli.62 In the 
second plausible mechanism, the lipoic acid bound to E2 is replaced with a chemical xenobiotic 
mimic, thereby altering the host and initiating an autoimmune reaction. An experimental study 
tested the reactivity of more than 100 potential xenobiotics bound to PDC-E2 with the sera of 
PBC patients and found that nine had increased reactivity as compared to the sera of controls, 
as well as the native form of PDC-E2. One of the xenobiotic identified is a chemical that is 
largely used in cosmetics, 2-octynoic acid.63 The last method is related to the unique apoptotic 
process in biliary epithelial cells, in which an intact PDC-E2 remains in the apoptotic bleb, 
which can also explain the targeted immune reaction to the biliary epithelial cells despite the 
ubiquitous distribution of PDC-E2.64 
1




The specific pathogenic role of AMA, the serologic hallmark of PBC, remains to be clearly 
defined. Evidence suggests that it may play a role in the disease process due to its ability to  
inhibit the enzymatic activity of PDC and the ability of IgA AMA to undergo transcytosis in 
biliary epithelial cells, potentially predisposing them to apoptosis.65,66 The loss of biliary 
epithelial cells is hypothesized to be carried out by autoreactive CD8+ and CD4+ T cells 
reacting to PDC-E2 infiltrating the portal tracts, which can also be detected at lower quantities 
in the peripheral blood and portal lymph nodes of patients.24,65,67  
Another contributor to the pathogenesis of PBC is the biliary HCO3- umbrella hypothesis. The 
cholangiocyte membranes are protected by an apical alkaline barrier that is established by the 
secretion of bicarbonate into the bile duct lumen. This maintains bile salts in a polar state and 
thus unable to cross the membrane. In PBC, anion exchanger 2 (Cl-/HCO3- exchanger) and 
type III inositoltriphosphate receptor are defective, which results in the barrier being 
compromised and resulting in partial protonation of bile salts.68 Consequently, the bile salts 
are rendered apolar and gain the ability to cross the cholangiocyte membrane, thereby 
inducing apoptosis and senescence. 
Complications 
As with other liver diseases, portal hypertension is a potential complication for PBC, although 
it predominantly affects patients with cirrhosis. Before the introduction of UDCA, the 
prevalence of esophageal varices over a median 5.6 years was reported as 31% in a 
prospective study.69 The development of esophageal varices was associated with a higher 
mortality risk in the same study, as the 1- and 3-year survival estimates were 83% and 59%, 
respectively. Ascites and hepatic encephalopathy are also complications that can be observed.  
Hepatocellular carcinoma (HCC) is another complication that can arise. It is observed at less 
frequent rates compared to portal hypertension, with rates of 0.7-3.6% in patients followed for 
3.6-6.8 years.70,71 However, patients with cirrhosis are at an increased risk for HCC, as well as 
those with older age, male sex, history of blood transfusions, and signs of portal 
hypertension.70–72 Furthermore, the development of HCC is associated with worse transplant-
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Natural history  
PBC is highly variable in terms of presentation, but also with regards to the disease course. 
Generally, patients with PBC have a diminished survival compared to age- and sex-matched 
individuals, which has been demonstrated in various patient populations. In the UK, it was 
demonstrated that untreated PBC patients had a 2.7-fold increase in adjusted mortality 
compared to the general population.73 In a geographically defined cohort from Northeast 
England of prevalent cases from 1987 and 1994 and of whom 37% received treatment, the 
standard mortality ratio (SMR) was 2.87 and the 10-year survival was approximately 45%. 
Interestingly, patients demonstrated an increased mortality rate even when only considering 
liver-unrelated deaths, as the SMR was 1.73.35 A Canadian population-based study from 1996 
to 2002 reported the same SMR of 2.87 and a 10-year transplant-free survival rate of 68%, 
although the patient’s treatment state was largely undefined.74 
First-line Treatment  
Ursodeoxycholic acid (3a, 7B-dihydroxy-5b-cholanic acid, UDCA), an endogenous bile acid 
that normally represents a minority (3%) of the bile acid pool, is the standard treatment for PBC 
and is required as life-long treatment.75,76 It was approved by the Food and Drug Administration 
(FDA) in 1997 for the treatment of PBC. There are three mechanisms of action through which 
UDCA is thought to exert its effects.76 First, the hydrophilic nature of UDCA protects 
cholangiocytes by reducing the cytotoxicity of bile and possibly reducing the concentration of 
hydrophobic bile acids as it becomes the predominant bile acid (40-50%). Secondly, UDCA 
can aid in the stimulation of hepatobiliary secretion. Third, it can inhibit the mitochondrial 
membrane permeability transition (MMPT) and thus prevent bile acid-induced apoptosis of 
hepatocytes, which it may also achieve through the stimulation of the survival pathway. The 
recommended dosage for UDCA is 13-15mg/kg per day. It has been demonstrated that 13-
15mg/kg and 23-25mg/kg result in greater improvements in ALP and AST, compared to 5-
7mg/kg, but 23-25mg/kg was not superior.77 Furthermore, appropriate dosage can improve the 
rates of response in patients who were initially non-responders.78 
The efficacy of UDCA was demonstrated in several large, randomized, double-blind, placebo-
controlled trials, all of which reported that UDCA improved liver biochemistry markers, 
including ALP, aminotransferases, bilirubin, cholesterol, and IgM as early as 3 months from 
the start of treatment.79–81 The Canadian trial demonstrated that treatment with UDCA for 2 
years improved histological features, but had no impact on symptom, liver transplantation or 
death.79 In the French trial, it was demonstrated that treatment with UDCA for 4 years slowed 
progression, as defined by hyperbilirubinemia, ascites, variceal bleeding, or encephalopathy, 
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and reduced the need for liver transplantation, and improved transplant-free survival.81 The 
American trial demonstrated that UDCA treatment for 2 years was associated with a delay in 
progression, albeit had no impact on symptoms, histology, liver transplantation or survival.80  
Research outside of the scope of clinical trials has demonstrated that UDCA delays 
histological progression specially in those with an early stage.82,83 Furthermore, UDCA has 
shown to delay the onset of esophageal varices, as the incidence of new varices at 4 years 
was 16% in UDCA-treated patients, but 58% in the placebo group.84 A meta-analysis on the 
impact of UDCA on pruritus or fatigue reported negative results.83 Further, whether UDCA 
can have an effect on liver transplantation or patient survival has been debated, mainly due 
to inconsistent results. A recent study performed by the Global PBC Study Group 
demonstrated a lower risk for liver transplantation or death in patients receiving UDCA as 
compared to those who did not receive UDCA (HR=0.46, 95% CI 0.40-0.52, P<0.001), 
irrespective of disease stage.85 The benefit of UDCA was also observed in those who did not 
achieve complete biochemical response. These results highlight the importance of using 
UDCA as first-line therapy for all patients with PBC.   
Biochemical Response 
The aim of treatment is to ultimately improve long-term clinical outcomes, for which early 
detection is hindered by the slow progressive nature of PBC. Therefore, the efficacy of 
treatment has been largely determined through an assessment of liver biochemistry, as these 
are the first to be altered with treatment and the fact that they are associated with clinical 
outcomes. There are various criteria based on liver biochemistry that have been developed in 
order to determine ‘response’ to treatment that were developed based on their association with 
clinical outcomes. The first study to demonstrate an association between biochemical 
parameters and clinical outcomes was from the Mayo clinic, in which patients with ALP <2 × 
ULN at 6 months were more likely to respond favourably over a 2-year period.86 This study 
was followed by a study from Barcelona that proposed response be assessed at 1 year and 
defined by a reduction of ALP greater than 40% from baseline, or normal levels at 1 year.87 
Patients who met these criteria had transplant-free survival similar to a control population. 
Further, an absence of response according to Paris-I criteria (Table 1) was an independent 
predictor of liver transplantation or death.88 Toronto response was based on the risk for 
progressive liver damage, as patients who did not achieve ALP<1.67×ULN at 2 years tended 
to have a one-stage progression in histology during extended follow-up.89 Distinct Paris criteria 
were defined for patients with early stage, defined by an early histologic stage or normal 
albumin and bilirubin, named Paris-II (Table 1).90 
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While most criteria require assessment at 1 year, it has been proposed that early response 
identification can be done as early as 6 months, with same or higher positive and negative 
predictive values.91 This is important being that patients who do not respond to UDCA will have 
a delay in effective therapy if response cannot determined until 1 year. To address the need 
for timely assessment of response, a score that employs pre-treatment parameters associated 
with the probability of response was developed in 2703 patients and validated in 460 patients. 
The goal was to predict response to treatment, which was defined as ALP<1.67×ULN at 1 
year. The parameters included in the score were ALP at diagnosis, bilirubin at diagnosis, 
aminotransferase at diagnosis, age, the time interval between diagnosis and the start of UDCA 
treatment, and the absolute difference in ALP from diagnosis.92  
The biochemical parameters included in these criteria are consistent with one another, as the 
majority either include ALP or bilirubin. In fact, both ALP and bilirubin have been strongly 
associated with long-term outcomes and deemed to be ‘reasonably likely to predict clinical 
benefit’, which has ultimately led to their inclusion as surrogate end points in clinical trials for 
novel therapies in PBC.93   
 
Table 1. Response criteria associated with clinical outcome 
Response Time of 
assessment 
Criteria 
Rochester, 199986 6 months ALP<2×ULN and/or Mayo risk score <4.5 
Barcelona, 200687 1 year >40% decrease in ALP from baseline or normal 
levels 
Paris-I, 200888 1 year ALP ≤3×ULN, AST≤2×ULN, and 
bilirubin≤1mg/dL 
Rotterdam, 200994 1 year Normal bilirubin and albumin given at least one 
was abnormal at baseline 
Toronto, 201089 2 years ALP<1.67×ULN 
Paris-II, 201190 1 year ALP≤1.5×ULN, AST≤1.5×ULN, and normal 
bilirubin  
Ehime, 201195 6 months Normal GGT or ≥70% decrease in GGT 
ALP, alkaline phosphatase; ULN, upper limit of normal; AST, aspartate aminotransferase; GGT, gamma-
glutamyl transpeptidase.  
 
Second-line therapies  
Response to UDCA is variable and approximately 30-40% of all patients who are treated do 
not demonstrate an adequate response and are therefore at continued risk for disease 
progression and complications of PBC.87,88 Further, even though UDCA is well tolerated by 
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most patients, poor tolerance has been reported in up 9% of patients.96 Thus, there is still a 
need for additional therapies to become available. 
Immunosuppressive therapies 
Given the autoimmune nature of PBC, various immunosuppressants have been evaluated for 
the treatment of PBC, including methotrexate, cyclosporine, colchicine, azathioprine, and 
colchicine.97–101 However, these trials did not support their use in PBC as major side effects 
were reported or they failed to demonstrate any benefit on liver biochemistry, histology, or 
survival.  
Farsenoid X receptor agonists 
Farsenoid X receptor (FXR) is a nuclear receptor that regulates the expression of genes 
essential for bile acid homeostasis. Chenodeoxycholic acid is the most potent endogenous 
FXR agonist.102 Obeticholic acid (OCA) is a semi-synthetic analogue of chenodeoxycholic acid 
that activates FXR with 100× greater strength.102 In 2016, OCA obtained FDA approval and 
became the first available therapeutic agent for PBC since the introduction of UDCA. This was 
prompted by the results from the PBC OCA International Study of Efficacy (POISE) phase III 
trial, which was a 12-month, double-blind randomized controlled trial.103 In this trial, 216 
patients with inadequate response to UDCA defined by ALP ≥1.67×ULN or abnormal bilirubin 
were randomized to receive OCA as adjuvant therapy or as monotherapy in patients that could 
not tolerate UDCA. There were three arms, placebo, 5-10mg OCA, and 10mg OCA. The 
endpoint of the study was a composite of ALP<1.67×ULN, a reduction in ALP of at least 15%, 
and normal bilirubin. The endpoint was reached by 46% and 47% of those in the 5mg and 5-
10mg arms, compared to 10% in the placebo arm. Notedly, pruritus was a common side effect 
of OCA that was dose-dependent and could affect up to 68% of patients in the highest dose 
group.  
The open-label extension study of OCA has demonstrated its long-term efficacy and safety, as 
ALP levels remains significantly lower throughout the duration of OCA, up to 4 years.104 
Pruritus and fatigue were observed in 77% and 33% of patients, respectively. The estimated 
survival benefit from OCA has been evaluated with the GLOBE and UK-PBC risk scores, 
suggesting that in comparison to placebo, patients treated with OCA (10mg) have a 26% 
(GLOBE) and 37% (UK-PBC) relative reduction from baseline to 1 year in the 10-year risk for 
liver transplantation or death.105 The reduction in risk was nevertheless noted in patients who 
did not meet the primary endpoint for POISE. Whether OCA provides true survival benefit is 
yet to be determined in the phase IV trial (COBALT). 




Fibrates act as ligands and exert their effects on the nuclear receptor peroxisome proliferator-
activated receptor (PPAR). The receptor can exist in three isoforms: PPAR-α, PPAR-δ, PPAR-
γ.106 The first open-label study of bezafibrate, a non-selective PPAR-agonist, in PBC 
demonstrated that this therapeutic agent alone or adjuvant to UDCA can reduce ALP and IgM 
levels and improve symptoms.107 Since then, there have been numerous studies involving 
bezafibrate or fenofibrate, all of which suggest similar findings.107–114 However, the most 
promising findings arise from the BEZURSO trial, the first large, phase III, placebo-controlled 
trial of bezafibrate in combination with UDCA.115 Patients with an incomplete response to 
UDCA according to Paris-II criteria were eligible for inclusion, in which 100 patients were 
randomized in a 1:1 ratio to receive 400mg/day of bezafibrate or placebo for 24 months.115 The 
primary endpoint of the study was complete biochemical response, defined by normal bilirubin, 
ALP, aminotransferases, albumin, and prothrombin index, and was met by 31% of patients 
that received bezafibrate. Additionally, 67% achieved ALP normalization. In contrast, none of 
the patients in the placebo arm met the primary endpoint and only 2% achieved ALP 
normalization. Progression of liver stiffness was hindered in the treatment arm, as liver stiffness 
measures decreased 15% from baseline but increased 22% in the placebo group, all while 
improving pruritus and fatigue. Further research is needed to determine the impact of 
bezafibrate on long-term clinical outcomes. In a Japanese cohort the estimated survival benefit 
of bezafibrate was evaluated in 118 patients that received UDCA for at least one year and 
subsequent combination therapy with bezafibrate for at least another year.116 The addition of 
bezafibrate was associated with a significant reduction in the GLOBE score as well as 
improved predicted transplant-free survival compared to pre-combination therapy. Further, in 
patients with normal bilirubin before the introduction of bezafibrate, combination therapy was 
associated with reduced risk for liver transplantation or liver-related death.116 
Liver transplantation  
In patients who reach end-stage liver disease, liver transplantation is the sole treatment option 
that can improve quality of life and patient survival.117 Still, the transplantation burden for PBC 
has reduced in recent years as the proportion of liver transplantations attributed to PBC and 
the absolute number has decreased in Europe and the United States.118–121 For example, from 
1995 to 2006, there was a reduction in the absolute number of liver transplantations for PBC 
in the United States with an average decrease of 5.4 cases per year in spite of the increase of 
249 transplants per year.120 In a study of the European Liver Transplantation Registry, the 
proportion of liver transplantations for PBC decreased from 1986 to 2015 from 20% to 4%. 118  
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Recurrence of PBC after liver transplantation is not uncommon and rates can range from 17% 
to 53%, which may be due to differences in patient population and follow-up time across 
studies.119,122,123 Given the persistence of AMA after liver transplantation and the possibility for 
normal liver biochemistry, a diagnosis of recurrent PBC can be made when a biopsy shows 
evidence of histological features consistent with a florid duct lesion.1 Although it has been 
shown that recurrent PBC can progress to cirrhosis in up to 15% of patients, earlier studies 
failed to demonstrate an impact on graft or patient survival.124,125 A recent study from the 
GLOBAL PBC Study Group of 785 patients from North America and Europe showed a 
significant time-dependent association between recurrent PBC and graft loss (HR=2.01, 95% 
CI 1.16-3.51) and death (HR=1.72, 95% CI 1.11-2.65).122 The factors found to be associated 
with recurrent PBC in this study were younger age at diagnosis and liver transplantation, 
tracolimus use, and biochemical markers of cholestasis 6 months after liver transplantation 
(bilirubin≥100µmol or ALP >3×ULN).  
Prediction of response and clinical outcomes  
Risk stratification of patients with PBC is important to determine the need for specialty care, 
vigilance, second-line therapies, and timing of liver transplantation, which can all be based on 
patient characteristics, as well as markers of disease severity. One of the first predictors of 
prognosis in patients with PBC that was applicable to all stages of disease was histologic 
stage. Multiple studies have demonstrated that an advanced histologic stage is associated 
with an increased risk for liver transplantation or death.126–128 Recognition of the prognostic 
value of histology in PBC in conjunction with the decreased rate of biopsies has prompted the 
use of non-invasive markers for fibrosis. One of these markers is APRI, whose association 
with transplant-free survival has been demonstrated and a threshold of 0.54 was established 
for use at baseline and 1 year, which suggests that values that surpass this threshold are 
associated with worse prognosis.128 Liver stiffness assessed by transient elastography has 
been associated with decompensation, liver transplantation, and death, with superiority to non-
invasive biochemical markers in diagnosing significant fibrosis, severe fibrosis, or cirrhosis.129  
Demographic factors, such as age and sex have been associated with response to UDCA and 
prognosis. Male sex has been proposed as being independently associated with decreased 
response to UDCA and increased mortality.36,74 Meanwhile, older age has been shown to be 
an independent predictor for higher response to UDCA according to Paris-II criteria and 
increased mortality.36,127 The impact of age, however, should be analyzed in comparison to an 
age- and gender-matched population since in older patients, mortality is often unrelated to 
PBC. In a study of asymptomatic patients, similar mortality rates between patients above 55 
year old and an age- and gender-matched population were reported.130 
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Hyperbilirubinemia, a reflection of  the severity of ductopenia and biliary piecemeal necrosis131, 
is one of the main predictors of prognosis in untreated and treated patients. An early study of 
untreated patients demonstrated that there is a period of rather stable bilirubin followed by a 
rapid rise in bilirubin of 2.5mg/dl per year that results in death.132 In the context of UDCA,  
patients who achieve normalization of bilirubin at 6 months have improved transplant-free 
survival compared to those without normalization.133 Multiple studies have confirmed the 
predictive value of elevated bilirubin on transplant-free survival.81,93,126,128 Bilirubin, along with 
albumin, is included in a three-tiered biochemical staging based on the finding that albumin 
and bilirubin were consistently associated with survival: early (normal bilirubin and albumin), 
moderately advanced (abnormal bilirubin or albumin), and advanced (abnormal bilirubin and 
albumin).134 Another major liver parameter often used is ALP, which has been associated with 
liver transplant-free survival, with increased predictive value when combined with bilirubin.93 
Accordingly, bilirubin and ALP, are some of the most common liver parameters included in 
response criteria (Table 1).  
One of the major limiting factors in the development of novel therapies for the treatment of 
PBC is its slowly progressive nature, which would require long-term follow-up to determine if a 
therapeutic agent influences clinical outcomes. Thus, surrogate endpoints such as ALP and 
bilirubin have been of great value, particularly for their convenience and non-invasive nature.  
Risk scores 
While response criteria are a simple way to determine prognosis, there is a loss in predictive 
value due to the dichotomization of continuous variables. In order to improve prognostic 
performance, various risk scores that culminate several variables have been developed 
specifically for PBC (Table 2). One of the earliest risk scores that employed non-invasive 
measurements to predict survival is the Mayo risk score. It was developed in 1989 from 312 
untreated PBC patients to predict survival up to 7 years, with the intended application for 
selecting patients for liver transplantation and its timing.135 The model was subsequently 
updated to predict short-term survival at 2 years and for use at any time during follow-up.136  
More recent models include the GLOBE score and UK-PBC, which were developed in UDCA-
treated patients. The development of the GLOBE score was conducted in globally 
representative cohort to predict transplant-free survival with values collected at 1 year, 
although it can also be used with values collected from 2-5 years.137 The performance of the 
GLOBE score was superior to that of binary response criteria. The UK-PBC risk score can be 
used to predict the risk of liver transplantation and liver-related death at 5, 10, and 15 years.138 
The UK-PBC risk score has been validated in a cohort from the United States with excellent 
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discrimination.139 Further, both scores have been validated in Chinese and Korean patient 
populations.140,141 Similarly, their performance was validated in a cohort that included centers 
from Europe, US, and Canada for the prediction of cirrhosis-related complications, with similar 
and excellent prognostic performance between the scores but improved compared to 
published response criteria.142  
 
Table 2. Risk scores developed for primary biliary cholangitis 
Prognostic score Year Purpose Variables 
Mayo Risk score135 1989 Predict survival, up to 7 years 
and select/timing patients for 
liver transplantation 
 Age 
 Total bilirubin (mg/dl) 
 Albumin (g/dl) 
 Prothrombin time 
 Severity of edema 
Mayo Risk score136 1994 Predict short-term survival (2 
years) 
 Age 
 Total bilirubin (mg/dl) 
 Albumin (g/dl) 
 Prothrombin time 
 Severity of edema 
GLOBE score137 2015 Predict transplant-free 




 Age at UDCA start 
 Bilirubin (×ULN) at 1 year 
 ALP (×ULN) at 1 year 
 Albumin (×LLN) at 1 year 
 Platelet count (×109/L) at 1 
year  
UK-PBC score138 2016 Predict liver transplantation 
and liver-related death at 5, 
10 and 15 years  
 
 
 ALP (×ULN) at 1 year 
 AST or ALT (×ULN) at 1 
year  
 Bilirubin (×ULN) at 1 year  
 Albumin (×LLN) at baseline  
 Platelet count (×LLN) at 
baseline 
UDCA, ursodeoxycholic acid; ULN, upper limit of normal; ALP, alkaline phosphatase; LLN, lower limit of 
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AIMS OF THESIS 
This thesis will utilize a large and globally representative cohort of patients with long-term 
follow-up to study patients with PBC. In Chapters 2 and 3, the aim is to describe temporal and 
spatial trends in PBC with regards to patient and disease characteristics and evaluate whether 
there are differences in clinical outcomes of patients according to calendar time or 
geographical region. Chapters 4, 5 and 6 aim to identify clinically relevant and important 
factors for risk stratification in PBC through the evaluation of individual prognostic factors as 
well as established risk scores that predict outcome. In Chapter 7 and 8, the aim is to optimize 
patient management, and thereby survival, through an establishment of care pathways for the 
need for referral and optimal biochemical treatment targets.  
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Changes over time in the presenting features and clinical course of patients with primary biliary 
cholangitis are poorly described. We sought to describe temporal trends in patient and disease 
characteristics over a 44-year period across a large international primary biliary cholangitis 
cohort of 4,805 patients diagnosed between 1970 and 2014, from 17 centers across Europe 
and North America. Patients were divided into five cohorts according to their year of diagnosis: 
1970-1979 (n = 143), 1980-1989 (n = 858), 1990-1999 (n = 1,754), 2000-2009 (n = 1,815), 
and ≥2010 (n = 235). Age at diagnosis, disease stage, response to ursodeoxycholic acid, and 
clinical outcomes were compared. Mean age at diagnosis increased incrementally by 2-3 years 
per decade from 46.9 ± 10.1 years in the 1970s to 57.0 ± 12.1 years from 2010 onward (P < 
0.001). The female to male ratio (9:1) and antimitochondrial antibody positivity (90%) were not 
significantly variable. The proportion of patients presenting with mild biochemical disease 
(according to Rotterdam staging) increased from 41.3% in the 1970s to 72.2% in the 1990s (P 
< 0.001) and remained relatively stable thereafter. Patients with a mild histological stage at 
diagnosis increased from 60.4% (1970-1989) to 76.5% (1990-2014) (P < 0.001). 
Correspondingly, response to ursodeoxycholic acid according to Paris-I criteria increased; 
51.7% in the 1970s and 70.5% in the 1990s (P < 0.001). Recent decades were also 
characterized by lower decompensation rates (18.5% in the 1970s to 5.8% in the 2000s, P < 
0.001) and higher 10-year transplant-free survival (48.4%, 68.7%, 79.7%, and 80.1% for each 
respective cohort; P < 0.001). Conclusion: In recent decades, a pattern of primary biliary 
cholangitis presentation consistent with an older age at diagnosis alongside reduced disease 
severity has been noted; the observed trends may be explained by an increase in routine 









Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by 
inflammation and destruction of the small intralobular bile ducts.1-3 The disease mainly affects 
middle-aged women and has a slow, progressive course that may lead to fibrosis, cirrhosis, 
and liver failure requiring liver transplantation. The standard treatment for PBC is 
ursodeoxycholic acid (UDCA) as its long-term use improves liver biochemistry, delays 
histological progression, and may improve transplant-free survival.4-6 However, up to 40% of 
patients can have an inadequate response to UDCA that is associated with reduced transplant-
free survival.4,7-9 
PBC is a rare disease with multiple studies reporting an increase in its incidence and 
prevalence in recent years.10-18 In a systematic review conducted by Boonstra et al.10, the 
incidence of PBC varied from 0.33 to 5.8 per 100,000/year, yet its temporal trends are 
conflicting as some studies suggest an increase11,12, while others do not substantiate this 
finding.19,20 The prevalence ranged from 1.91 to 40.2 per 100,000, and all investigated studies 
reported an increase.10 An increase in prevalence impacts how PBC contributes to the health 
care system and may be a result of multiple societal and disease factors. It is important to note 
that initial reports of an increasing prevalence began during the off-label use of UDCA period, 
which suggests that the increased prevalence in the UDCA era may be due to prolonged 
survival.11,14,16 Correspondingly, the absolute number of liver transplantations for PBC has 
decreased in Europe and the United States since the introduction of UDCA in the early 
1990s.3,9,21-23  
In addition to epidemiological changes, the clinical presentation of PBC has changed over the 
years. Whereas most patients presented with an advanced histological stage in earlier 
decades, nowadays most patients present during an asymptomatic stage.24,25 Therefore, the 
underlying assumption that PBC, as a disease, is a static entity may not be accurate. We used 
a representative large cohort of patients with PBC to assess how disease presentation and 
prognosis have changed over the last nearly 50 years.  In doing so, we provide long-term 
insight into the changing nature of PBC in clinical practice. 
  
38   |   Chapter 2
 
 
PATIENTS AND METHODS 
Population and study design  
This was a retrospective study based on patient data retrieved from the Global PBC Study 
Group database, the characteristics of which have been described in previous publications.26, 
27 The database comprises long-term follow-up cohorts from 17 centers across North America 
and Europe. UDCA-treated and non-treated patients aged ≥18 with an established PBC 
diagnosis from 1970 to 2014, according to internationally accepted guidelines, were included 
in the study.3,28,29 Patients with either a short follow-up (<6 months), an unknown date of 
important clinical events, an overlap syndrome, or another concomitant liver disease were 
excluded. Completeness and accuracy of the database was established through visits to 
individual centers. This study was conducted in accordance with the 1975 Declaration of 
Helsinki. The protocol was approved by the institutional research board of the corresponding 
center and at all participating centers per local regulations.  
Data collection  
In the established database, study entry (baseline) was the date of UDCA therapy initiation or 
the date of first visit for nontreated patients. The following demographic and clinical data were 
available at study entry: sex, date of birth, date of diagnosis, anti-mitochondrial antibody (AMA) 
serological status, liver histology, biochemical disease stage, and UDCA therapy (if received 
and dosage). In addition, the following laboratory values were available at study entry and 
every 6-12 months until the end of follow-up: alkaline phosphatase, aspartate 
aminotransferase, alanine aminotransferase, total bilirubin, albumin, and platelet count. 
Histology was considered if the liver biopsy was completed within 24 months of diagnosis date 
and dichotomized according to Ludwig et al.’s30 and Scheuer’s31 classification; specifically, as 
mild (stage I and II) and advanced (stage III and IV). The Rotterdam criteria were used to 
determine patients’ biochemical stage. According to these criteria, mild stage is defined as 
normal bilirubin and albumin, moderate stage is defined as abnormal bilirubin or albumin, and 
advanced stage is defined as abnormal bilirubin and albumin.9,32 Baseline aspartate 
aminotransferase/platelet ratio index, an independent predictor of transplant-free survival, was 
calculated to stratify patients at risk of liver transplantation and death based on a threshold of 
0.54.33 The first occurrence of hepatic decompensation (ascites, variceal bleeding, or hepatic 
encephalopathy), hepatocellular carcinoma (HCC), liver transplantation, or all-cause mortality 
was also retrieved.  
In patients who received therapy, biochemical response to UDCA was determined according 
to Barcelona, Paris-I, Rotterdam, Toronto, and Paris-II criteria.7-9,34,35 In addition, the GLOBE 
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score was compared to age-specific thresholds to determine UDCA-response.26 Patients were 
considered responders if their GLOBE score did not surpass their age-specific threshold.  
Statistical analysis 
Patients diagnosed between 1970 and 2014 were divided into five cohorts according to their 
year of diagnosis: 1970-1979, 1980-1989, 1990-1999, 2000-2009, and ≥2010. To compare 
patient and disease characteristics across the five cohorts, we conducted chi-squared tests for 
categorical variables and analyses of variance for continuous data. P < 0.05 was considered 
significant for all statistical analyses. Significant results were further analyzed to correct for any 
possible confounding variables and to assess the influence of other explanatory variables on 
the outcome measure. A multivariable logistic regression was applied to binary outcomes, such 
as biochemical response to UDCA, biochemical disease stage (moderate and advanced 
disease stage grouped as advanced), and histological stage (odds ratio with 95% confidence 
interval [CI]).  
For time-to-event analyses, patients diagnosed from 2010 onward were excluded due to a 
shorter follow-up period than the other cohorts. Patients without an event and those who were 
lost to follow-up were censored at their last visit.  The rates of hepatic decompensation, HCC, 
and liver transplant-free survival were assessed by Kaplan-Meier estimates and compared 
across decades using the log-rank test. If decompensation occurred within the first year of 
study entry, the patient was excluded from the time-to-event analysis for decompensation. 
Transplant-free survival of the PBC population was also compared within each decade to an 
age- and gender-matched Dutch population. These outcomes were also estimated by Cox 
proportional hazards’ modeling (hazards ratio [HR] with 95% CI). 
Demographic and clinical characteristics are presented as count (percentage) for categorical 
data and mean ± standard deviation (SD) for continuous variables. Laboratory values are 
presented as median (interquartile range [IQR]). Data that were not normally distributed were 
log-transformed for the analyses. All analyses were two-sided and were performed using IBM 
SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY).  
RESULTS 
Study population characteristics 
A total of 4,805 PBC patients, diagnosed between 1970 and 2014, were included and divided 
into five cohorts according to their year of diagnosis (Table 1, Table S1): 143 patients were 
diagnosed from 1970 to 1979, 858 patients from 1980 to 1989, 1,754 patients from 1990 to 
1999, 1,815 patients from 2000 to 2009, and 235 patients from 2010 onward. The 
characteristics of each cohort are presented in Table 1. The median follow-up times for the 
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five respective cohorts were: 6.7 years (IQR 3.0-14.3), 8.9 years (IQR 4.0-14.7), 10.0 years 
(IQR 6.0-13.9), 5.6 years (IQR 3.4-8.3), and 1.6 years (IQR 1.0-2.1). The mean time from 
diagnosis to study entry was variable for each cohort: 11.1 years (SD 7.0) for the 1970s, 5.1 
years (SD 4.5) for the 1980s, 1.4 years (SD 2.3) for the 1990s, 0.4 years (SD 1.1) for the 
2000s, and 0.1 years (SD 0.2) from 2010 onward. To consider this variation, all analyses were 
repeated in a subgroup of patients (n = 3,518) with a maximum 2-year lag between diagnosis 
and study entry, which included 14%, 29%, 76%, 93%, and 100% of patients from the main 
analysis in each respective cohort (Table S2).  
Age and sex trends 
The mean age at diagnosis increased incrementally from 46.9 ± 10.1 years in the 1970s to 
57.0 ± 12.1 years from 2010 onward (P < 0.001) (Figure 1A). This trend was consistent across 
center, sex, and biochemical disease stage (Figure S1A-C). The effect of calendar time on 
the increase in age at diagnosis remained significant (P < 0.001) after correcting for sex (Table 
S3). Furthermore, the age distribution of patients notably changed over the investigated 
decades (P < 0.001) (Figure 1B).  The proportion of patients aged 50-59 years at diagnosis 
remained relatively stable across the years, whereas the proportion of patients <50 years of 
age decreased and that of patients ≥60 years of age increased. There was no significant 
temporal trend in the female to male ratio, which remained approximately 9:1 (Table 1).  
 
 
Figure 1. Age at diagnosis of PBC patients across different decades. A) Mean age (± standard 
deviation) at diagnosis (dots) and estimated marginal means (squares) obtained after adjusting 
for sex. B) Distribution of age groups over calendar time.  
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Liver biochemistry and serological status 
The proportion of patients that were AMA-positive did not significantly differ across the 
investigated decades (Table 1). Median alkaline phosphatase and bilirubin values (times the 
upper limit of normal) at study entry decreased, while circulating platelet counts were noted to 
increase (P < 0.001), which collectively suggests a less advanced disease stage. The 
proportion of patients with alkaline phosphatase values <2 times the upper limit of normal 
increased gradually from 30.0% in the 1970s to 63.1% from 2010 onward (P < 0.001) (Figure 
2A). The proportion of patients with normal serum bilirubin concentrations also increased from 
51.1% in the 1970s to 77.6% in the 1990s, after which it remained relatively stable (P < 0.001) 
(Figure 2B). Furthermore, a reduced percentage of patients with aspartate 
aminotransferase/platelet ratio index >0.54 at study entry was observed (Table 1).  
Trends in biochemical and histological disease stage 
There was a gradual increase in the proportion of patients presenting with a mild biochemical 
disease stage from the 1970s to 1990s and remained stable thereafter (P < 0.001) (Figure 
2C). In a multivariable logistic regression, calendar time was a significant predictor for 
biochemical disease stage (P < 0.001) after adjusting for sex and age at diagnosis. Earlier 
decades were associated with an advanced biochemical disease stage. 
Out of 2,831 patients who underwent liver biopsy at diagnosis, 2,217 patients had histological 
disease stage available and were included in a subgroup analysis that combined cohorts due 
to the limited number of biopsies in the first and last cohorts. There were 326 biopsies from 
1970 through 1989, 948 biopsies from 1990 through 1999, and 943 from 2000 through 2014. 
The proportion of patients with a mild histological stage (I or II) at diagnosis increased with 
time (Table 1, Figure 2D). In a multivariable logistic regression, calendar time was a significant 
predictor for histological stage after adjusting for sex and age at diagnosis (P < 0.001). 
Trends in UDCA response rates  
The proportion of patients who ever received UDCA increased across the investigated 
decades (P < 0.001) (Table 1). In patients who received UDCA, the median number of years 
between diagnosis and the start of UDCA therapy decreased across the respective cohorts 
(1970s to ≥2010): 12.6 years (IQR 10.6-16.1), 4.4 years (IQR 2.1-8.1), 0.23 years (IQR 0.0-
2.0), 0.05 years (IQR 0.0-0.41), and 0.0 years (IQR 0.0-0.04). Additionally, the median initial 
dosage of UDCA received by patients across the five respective cohorts increased: 9.4 
mg/kg/day (IQR 8.5-11.0), 10.0 mg/kg/day (IQR 8.7-13.7), 12.2 mg/kg/day (IQR 9.2-14.7), 
13.5 mg/kg/day (IQR 11.1-15.3), 13.3 mg/kg/day (IQR 11.1-15.1). 
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Figure 2. Study entry characteristics associated with disease severity of patients diagnosed in 
different decades. A) Percentage of patients with alkaline phosphatase (ALP) above or below 
2 times the upper limit of normal (×ULN). B) Percentage of patients with bilirubin above or 
below 1×ULN. C) Percentage of patients corresponding to each biochemical stage according 
to Rotterdam criteria9; mild (normal albumin and bilirubin), moderate (abnormal albumin or 
bilirubin), advanced (abnormal albumin and bilirubin). D) Percentage of patients corresponding 
to each histological stage at diagnosis according to Ludwig et al.’s30 and Scheuer’s31 
classification: mild (stage I and II) or advanced (stage III and IV). 
 
The proportion of UDCA responders according to Paris-I, Toronto, Paris-II, Rotterdam, and 
GLOBE score criteria increased over the investigated decades (P < 0.001), but not according 
to Barcelona criteria (Figure 3, Table S4). Importantly, this trend remained true in patients 
who did not meet the individual criteria at baseline (Table S5). In a multivariable logistic 
regression, calendar time was not a significant predictor for UDCA response according to 
Paris-I criteria (Table 2). Response was associated with an increased age at diagnosis, and 
lower alkaline phosphatase and bilirubin levels (P < 0.001). Additionally, calendar time was 
also not a significant predictor for UDCA response according to Toronto, Paris-II, Rotterdam, 
and GLOBE score criteria (results not shown). 
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Figure 3. Response rates to ursodeoxycholic acid (UDCA) therapy over calendar time. 
Response was determined according to various published criteria: Barcelona, Paris-I, 
Rotterdam, Toronto, Paris-II, and the GLOBE score.7-9,26,34,35 Response rates according to all 
criteria were significantly different over calendar time (p<0.001), except Barcelona criteria 
(p=0.19). 
 
Table 2. Multivariable logistic regression for the attainment of biochemical response 
according to Paris-Ia (n=2283)   
Variable OR  95% CI p-value  
Male sex 0.90 0.63-1.29 0.58 
Year of diagnosis    0.67 
     1970-1979  1.00   
     1980-1989 0.80 0.37-1.71 0.66 
     1990-1999  1.01 0.44-2.37 0.96 
     2000-2009 0.97 0.40-2.32 0.94 
     ≥2010  0.92 0.33-2.57 0.88 
Age at diagnosis   0.04 
     <30 1.00   
     30-39  1.29 0.53-3.15 0.57 
     40-49  1.41 0.60-3.33 0.44 
     50-59  1.95 0.82-4.59 0.13 
     60-69  2.06 0.86-4.96 0.11 
     ≥70  2.06 0.82-5.21 0.13 
Log bilirubin (×ULN) 0.01 0.01-0.02 <0.001 
Log ALP (×ULN) 0.12 0.08-0.18 <0.001 
Difference between diagnosis and study entry (years)   0.98 0.94-1.03 0.44 
OR, odds ratio; CI, confidence interval; ULN, upper limit of normal; ALP, alkaline phosphatase. 
 
aResponse rate according to Paris-I is defined as: ALP ≤3 ×ULN, AST ≤2 ×ULN, and normal bilirubin after 1 
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Decompensation, HCC, and transplant-free survival 
The 10-year incidence rate of hepatic decompensation (ascites, variceal bleeding, or hepatic 
encephalopathy, whichever came first) decreased over time: 18.5% in the 1970s, 13.7% in 
the 1980s, 8.5% in the 1990s, and 5.8% in the 2000s (Figure 4Ai). All pairwise comparisons 
were significantly different, except the difference between the 1970s and 1980s cohorts (P = 
0.45). In a multivariable Cox regression, a temporal trend of lower decompensation risk was 
observed after adjusting for sex and age at diagnosis (Figure 4Bi) (P = 0.07). Calendar time 
as a continuous variable was a significant predictor for hepatic decompensation (HR, per 10-
year increase: 0.57, 95% CI 0.44-0.75, P < 0.001).  
The 10-year HCC incidence rates across the investigated decades were: 10.3%, 4.0%, 2.1%, 
and 2.3%, respectively (Figure 4Aii). The Kaplan-Meier estimate of cumulative HCC incidence 
was significantly higher in the 1970s compared to the 1980s (P = 0.01), 1990s (P < 0.001), 
and 2000s (P < 0.001). In a multivariable Cox regression, calendar time was not a significant 
predictor for HCC risk (P = 0.68) after adjusting for sex, age at diagnosis, and UDCA treatment 
(Figure 4Bii).  
The 10-year liver-related death rate decreased from 1970 through 2009: 34.6%, 13.2%, 5.6%, 
and 6.4% (P < 0.001). Furthermore, the 10-year transplant-free survival rate improved over 
the four respective investigated decades: 48.4%, 68.7%, 79.7%, and 80.1% (Figure 4Aiii). 
There was a significant difference in transplant-free survival between the 1970s and 1980s (P 
< 0.001), and between the 1980s and 1990s (P < 0.001). However, the transplant-free survival 
rates between the 1990s and 2000s were equivalent (P = 0.80). In a multivariable Cox 
regression, calendar time remained an independent predictor of transplant-free survival, and 
earlier decades were associated with an increased risk for liver transplantation and all-cause 
mortality (Figure 4Biii, Table S6). Furthermore, the 10-year transplant-free survival of PBC 
patients has improved even when compared to an age- and gender-matched general 
population (1970s: HR = 4.38, 95% CI 3.54-5.43, P < 0.001; 1980s: HR = 2.90, 95% CI 2.60-
3.24, P < 0.001; 1990s: HR = 2.14, 95% CI 1.94-2.36, P < 0.001; 2000s: HR = 1.93, 95% CI 
1.69-2.21, P < 0.001). 




Figure 4. Time-to-event analyses of decompensation, hepatocellular carcinoma (HCC), and 
liver transplantation or death over calendar time. A) Kaplan-Meier (crude) and B) Multivariable 
Cox regression (adjusted) estimates of i) cumulative incidence of decompensation, ii) 







































































































































































In this study of a large, internationally representative cohort of PBC patients, we demonstrate 
that patients diagnosed in recent decades are older and have a milder disease stage compared 
to patients diagnosed in earlier decades. In addition, more patients respond favourably to 
UDCA therapy and have improved transplant-free survival. These results provide unique 
insight into the possible changing natural history of PBC over the last five decades. It is 
noteworthy to mention that similar results have been observed in a study from Sweden that 
included 246 patients diagnosed with primary sclerosing cholangitis between 1984 and 2004. 
Bergquist et al. reported an increase in age at diagnosis and lower frequency of symptoms in 
patients diagnosed after 1998.36 
Although some of the observed trends could be potentially attributed to more sensitive AMA 
tests that detect the disease at an earlier stage, we speculate that any changes in AMA testing 
have not had a major impact in the observed temporal trends. The conventional method of 
AMA detection is indirect immunofluorescence, yet there has been an increase in enzyme-
linked immunosorbent assay-based assays and immunoblotting that have led to greater 
sensitivity and specificity.37 These improvements would translate to an increase in the 
proportion of AMA-positive patients, however, this has remained unchanged.  
We demonstrate a 10-year increase in the mean age at diagnosis from 1970 to 2014. A similar 
increase was reported in a Canadian PBC population, in which prevalent cases in 1996 had a 
median age of 53, whereas prevalent cases in 2002 had a median age of 57.18 These numbers 
coincide with the findings from our study, in which the mean age at diagnosis in the 1990s and 
2000s is 52.8 and 55.0 years, respectively. Furthermore, an increased proportion of patients 
diagnosed in recent years are over 50 years of age and account for 71.5% of patients 
diagnosed on 2010 and beyond. Comparable results were found within the UK-PBC cohort, in 
which 75% of patients prevalent between 2008 and 2010 were over 50 years of age.38  
The increase in age may be attributed to the general aging of the population as the median 
age in North America and Europe has reportedly increased from 30 in 1970 to 40 in 2015.39 
This represents a 10-year increase over a 45-year period, which is similar to the 10-year 
increase in age at diagnosis we observe over a 44-year interval. Furthermore, the 34% 
absolute increase of PBC patients 50 years old and above from 1970 to 2014 was greater than 
that of the general population, which was only 11% (25% in 1970 to 36% in 2015) (39). The 
increase in age may also be attributed to differences in the trigger for a PBC diagnosis over 
the years. Although we are not able to assess the symptoms in our cohort, we speculate that 
patients in recent decades are predominantly asymptomatic and are therefore diagnosed when 
they see their physician to undergo routine testing of liver function, which occurs more 
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frequently in older individuals. Conversely, younger patients in earlier decades were more 
likely to develop symptoms, which led to their diagnoses.40,41 Lastly, the increase in age may 
be disease-specific and represent a shift in the natural history of PBC towards a new older at-
risk population, considering the increase in age was observed irrespective of biochemical 
disease stage. It can also be speculated that the later onset is a result of a prolonged 
subclinical disease period and potentially a delayed exposure to an unknown environmental 
trigger due to temporal changes in lifestyle.  
An older age at diagnosis is clinically important because it has been associated with an 
increased likelihood of meeting Paris-I criteria for response to UDCA.38 Similarly, we found an 
older age at diagnosis to be an independent predictor of Paris-I response, yet calendar time 
was not a significant predictor. These results indicate the increase in age at diagnosis may be 
an important factor contributing to the increase in UDCA response rather than calendar time 
itself. Furthermore, the low response rates observed in earlier decades can be a result of 
inadequate UDCA dosages and the delay in treatment. The importance of an adequate UDCA 
dosage of 13-15mg/kg/day has been emphasized in a study that found 40% of UDCA 
nonresponders in whom the dosage was increased became responders.42,43  
In recent decades, patients present at an older age, yet they have milder biochemical and 
histological disease stage. Improved disease severity might be explained by an earlier 
detection of PBC due to improved disease awareness leading to liver function tests and AMA 
assays.44,45 The histological disease stage at diagnosis has important prognostic implications 
for UDCA response and survival. Advanced histological stages are associated with an 
increased risk of treatment failure.8 In addition, the survival of UDCA-treated patients in stage 
I/II is similar to that of an age- and sex-matched control population, while the probability of liver 
transplantation or death is significantly increased in patients with advanced histological 
stages.46 
Although a decrease in the number of liver transplantations for PBC has been reported over 
the years22, an improvement in transplant-free survival has not been documented. In a 
Canadian population-based study of patients diagnosed between 1996 and 2002, Myers et al. 
did not observe a significant difference in survival according to year of diagnosis.18 The lack of 
difference in survival may be attributed to the small interval of study, which only spanned 6 
years. The reported increase in median age of the general population well reflects an increase 
in life expectancy over time39; therefore, transplant-free survival of PBC patients was compared 
to that of the general population.  Our study showed that transplant-free survival improved over 
a 44-year period, even when compared to the general population, and supports its potential 
role in the increased prevalence of PBC.   
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The inclusion of a large population of PBC patients from different geographical regions, long-
term follow-up, and broad study period are some of the strengths of our study. However, some 
limitations need to be considered. First, the 1970s and 1980s cohorts were susceptible to a 
delay in documentation since study entry can be many years after the date of diagnosis in 
these cohorts. As such, the difference in years between these two dates was included in all 
multivariable analyses and we assessed a subgroup of patients with a maximum 2-year 
difference. The same trends emerged in the subgroup analyses, thus excluding the possibility 
that the delay in documentation is the reason for an advanced disease in the early cohorts. 
Second, due to the retrospective nature of the study, biochemical data were not available for 
all patients, and thus, response to UDCA could not be determined for all patients. To account 
for missing laboratory values, all analyses were repeated in an imputed dataset and revealed 
similar results. Lastly, the trends observed in our study cohort could not be assessed for 
correlations with symptom profiles or various environmental factors previously associated with 
PBC, such as smoking, age at first pregnancy, and the use of hormonal replacement therapy.47 
Even though the trends observed may be due to a selection of patients whose diagnosis is 
triggered by symptoms or complications in earlier decades rather than routine liver function 
tests as in recent decades, we describe the presenting characteristics of a typical PBC patient 
seen by physicians and how they have changed over time. The observed temporal trends 
warrant further investigation in other PBC populations to determine whether they are 
universally applicable and to explore the potential influence of a changing environmental 
trigger. 
In conclusion, we demonstrate a 10-year increase in age at diagnosis accompanied by milder 
disease severity at presentation of PBC patients. These findings provide the most 
comprehensive evidence of a changing natural history of PBC to date.    
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Table S3. Factorial ANOVA analysis of age at diagnosis over calendar time adjusting for sex  
 
N=4804 Beta coefficient  Lower 95% CI Upper 95% CI p-value  
Male    4.03  2.93  5.14 <0.001 
Female   0.00    
Year of diagnosis 1970-1980 -10.00 -12.43 -7.57 <0.001 
Year of diagnosis 1980-1990 -6.83 -8.51 -5.14 <0.001 
Year of diagnosis 1990-2000 -4.17 -5.76 -2.58 <0.001 
Year of diagnosis 2000-2010 -2.00 -3.58 -0.41   0.014 
Year of diagnosis ≥2010   0.00    
ANOVA, analysis of variance; CI, Confidence interval. 
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Table S6. Multivariable Cox regression analysis of 10-year transplant-free survival (n=3354) 
 
Variable  HR 95% CI p-value  
Male sex 1.11 0.89-1.40   0.350 
UDCA 0.55 0.45-0.68 <0.001 
Year of diagnosis   <0.001  
     1970-1979 1.00    
     1980-1989 1.14 0.81-1.60   0.454  
     1990-1999 0.72 0.49-1.06   0.095  
     ≥2010 0.60 0.40-0.89   0.011  
Age at diagnosis    <0.001  
     <30 1.00    
     30-39  1.45 0.58-3.63   0.423  
     40-49  2.31 0.95-5.63   0.066  
     50-59  2.34 0.96-5.71   0.061  
     60-69  4.46 1.82-10.89   0.001  
     >70  8.52 3.45-21.07 <0.001  
Log bilirubin (×ULN) 12.8 10.6-15.4 <0.001  
Difference between diagnosis and study entry (years) 1.06 1.03-1.08 <0.001  
HR, hazard ratio; CI, confidence interval; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.  
3CHAPTER 3
The impact of geographical region 
on outcomes of patients with 
primary biliary cholangitis from 
Western Europe
Murillo Perez CF, Gerussi A, Trivedi PJ, Corpechot C, 
van der Meer AJ, Battezzati PM, Lindor KD, Nevens F, 
Kowdley KV, Bruns T, Cazzagon N, Floreani A, Tanaka A, Ma X, 
Mason AL, Gulamhusein A, Ponsioen CY, Carbone M, Lleo A, 
Mayo MJ, Dalekos GN, Gatselis NK, Thorburn D, Verhelst X, 
Parés A, Janssen HLA, Hirschfield GM, Hansen BE, Invernizzi P, 
Lammers WJ
4CHAPTER 4
Effects of age and sex of response 
to ursodeoxycholic acid and 
transplant-free survival in patients 
with primary biliary cholangitis
Cheung AC*, Lammers WJ*, Murillo Perez CF, van Buuren HR, 
Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, 
Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, 
Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV,
Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, 
Poupon R, Janssen HLA, Hansen BE
*shared first co-authorship
Clinical Gastroenterology & Hepatology, 2019




Background & Aims: Primary biliary cholangitis (PBC) predominantly affects middle-aged 
women; there are few data on disease phenotypes and outcomes of PBC in men and younger 
patients. We investigated whether differences in sex and/or age at the start of ursodeoxycholic 
acid (UDCA) treatment are associated with response to therapy, based on biochemical 
markers, or differences in transplant-free survival. 
Methods: We performed a longitudinal retrospective study of 4355 adults in the Global PBC 
Study cohort, collected from 17 centers across Europe and North America. Patients received 
a diagnosis of PBC from 1961 through 2014. We evaluated the effects of sex and age on 
response to UDCA treatment (based on GLOBE score) and transplant-free survival using 
logistic regression and Cox regression analyses, respectively. 
Results: Male patients were older at the start of treatment (58.3±12.1 years vs 54.3±11.6 
years for women; P<.0001) and had higher levels of bilirubin and lower circulating platelet 
counts (P<.0001). Younger patients (45 years or younger) had increased serum levels of 
transaminase than older patients (older than 45 years). Patients older than 45 years at time of 
treatment initiation had increased odds of a biochemical response to UDCA therapy, based on 
GLOBE score, compared to younger patients. The greatest odds of response to UDCA were 
observed in patients older than 65 years (odds ratio compared to younger patients 45 years or 
younger, 5.48; 95% CI, 3.92–7.67; P<.0001). Risk of liver transplant or death (compared to a 
general population matched for age, sex, and birth year) decreased significantly with 
advancing age: hazard ratio for patients 35 years or younger, 14.59 (95% CI, 9.66–22.02) vs 
hazard ratio for patients older than 65 years, 1.39 (95% CI, 1.23–1.57) (P<.0001). On 
multivariable analysis, sex was not independently associated with response or transplant-free 
survival. 
Conclusion: In longitudinal analysis of 4355 adults in the Global PBC Study, we associated 
patient age, but not sex, with response to UDCA treatment and transplant-free survival. 
Younger age at time of treatment initiation is associated with increased risk of treatment failure, 
liver transplant, and death. 
  
4




Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease in which 
patient outcome is largely dictated by the development of cirrhosis and portal hypertension.1,2 
Between 83 to 95% of patients are women, most often presenting between 40 and 60 years of 
age.3  
Several studies have demonstrated that the clinical impact of PBC differs according to sex and 
age group.3,4 Compared with male patients, female patients are more frequently symptomatic, 
with an increased burden of pruritus5,6 and greater scores in the fatigue domain of the PBC-40 
quality of life questionnaire.7 In contrast, male PBC patients are more likely to present with 
advanced disease5-7, harbor an increased risk for hepatocellular carcinoma8, and appear to 
have significantly worse transplant-free survival.4,9 Male sex has also recently been identified 
as a risk factor for non-response to ursodeoxycholic acid (UDCA) independent of age at 
presentation, presence of portal hypertension, and biochemical indices of disease severity7, 
alluding to the possibility of a more rapidly progressive disease course. Age appears to add 
another layer of complexity to clinical phenotypes, because a study conducted by the UK-PBC 
consortium recognized that younger patients are affected by more severe pruritus and fatigue. 
Furthermore, there was a positive correlation between older age at presentation and response 
to UDCA in female patients; with a lesser impact evident in patients of male sex.7  
The aim of this study was to validate the prognostic impact of presenting age and sex on 
treatment responses and transplant-free survival using a large, internationally representative 
cohort of patients with PBC.  
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PATIENTS AND METHODS 
Subjects and study design  
This was a longitudinal study of treatment response and transplant-free survival according to 
age and sex in a well-defined cohort from the Global PBC Study Group. Demographic, clinical, 
and outcome data were collected from 17 centers across Europe and North America. Patients 
with a short follow-up (<6 months), overlap syndrome, or another concomitant liver disease 
were excluded. This study included adult patients (≥18 years of age) diagnosed between 1961 
and 2014 with PBC as defined by published criteria1,10 and who were treated with UDCA.   
Baseline was defined as the date of UDCA initiation. The primary endpoints were biochemical 
response as per the GLOBE score criteria11 (GLOBE score below the age-specific threshold) 
and liver transplant-free survival. Secondary endpoints included biochemical response 
according to the following response criteria: Barcelona, Paris-I, Rotterdam, Toronto, and Paris-
II. Patients who did not meet clinical endpoints (liver transplant or death) were censored at 
their last date of available follow-up. The protocol was reviewed and approved by all local 
Institutional Review Boards across the 17 centers. 
Statistical analysis  
Continuous data are expressed as mean ± standard deviation (SD) or median and interquartile 
range (IQR) as appropriate, and categorical data as proportions. Unpaired t-test, Mann-
Whitney U test, or analysis of variance was used to determine whether there was a significant 
difference for continuous data, and differences in categorical data were analyzed by using the 
Chi-square test. Life table analysis was conducted to assess the effect of age on transplant-
free survival in PBC patients when compared with a control Dutch population. PBC patients 
were stratified into various age groups, after which they were independently analyzed relative 
to the control population matched for age, sex, and birth year. Unadjusted differences in 
transplant-free survival between male and female patients were assessed using Kaplan-Meier 
estimates and compared by using the log-rank test. Univariable and multivariable associations 
were computed using a logistic regression for biochemical response (odds ratio [OR] and 95% 
confidence interval [CI]) and Cox proportional hazards regression for transplant-free survival 
(hazard ratio [HR] and 95% CI). Univariable analysis included sex, age at UDCA initiation, year 
of diagnosis, histologic stage at baseline as defined by the criteria of Scheuer12 and Ludwig et 
al3, biochemical stage at baseline as defined by ter Borg et al.14 (mild: normal bilirubin and 
albumin, moderately advanced: either abnormal bilirubin or albumin, advanced: abnormal 
bilirubin and albumin), biochemical response, and surrogates of portal hypertension (platelet 
count <150×109/L).15,16 Age at UDCA initiation was analyzed as a continuous and categorical 
variable (grouped as <35, 36-45, 46-55, 56-65, and >65 years) to allow for an equitable 
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distribution during analysis. To account for the lack of an adequate threshold of response for 
the age group ≤35, age was analyzed in the following age groups for response to UDCA (≤45, 
46-55, 56-65, and >65 years). The association of age with response was further assessed with 
a restricted cubic spline function with three knots. To determine whether age was an 
independent determinant of response in various subgroups, patients were categorized into 2 
groups, according to whether their GLOBE score at baseline was below or above the age-
specific threshold (GLOBE score status at baseline). An interaction between age and sex, and 
age and GLOBE score status at baseline were included in the analysis. 
All analyses were performed using multiple imputation by Markov chain Monte Carlo method 
for missing data (Proc MI in SAS version 9.3). Multiple imputation was based on the 
assumption that data were missing at random, with 10 imputed datasets created from iterations 
to reduce sampling variability. Rubin’s rules were used for the estimation of parameters of 
interest and standard error.17,18 The variables included in the process of imputation were: 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase 
(ALP), total bilirubin, albumin, and platelet count.  
A two-sided P-value of <.05 was considered statistically significant. Statistical analyses were 
performed using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, 
USA) and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).   
RESULTS 
Patient characteristics 
For the current study, a total of 4355 UDCA-treated PBC patients were analyzed after 
excluding those <18 years of age (n=3) and with no (n=647) or unknown treatment status 
(n=96). Four hundred forty-six (10%) were male, and 3909 (90%) were female with a median 
follow-up of 7.7 years (IQR 3.9-12.0); 576 patients died (276 deaths were liver-related) and 
330 patients underwent transplantation.  
Clinical differences at baseline between sexes and age groups 
At the time of UDCA initiation, male patients were older than female patients (58.3 ± 12.1 years 
vs 54.3 ± 11.6 years, P<.0001), exhibited greater median serum bilirubin values (0.82 ×ULN 
[IQR 0.59-1.49] vs 0.62 ×ULN [IQR 0.44-1.00], P<.0001) and were more often 
thrombocytopenic (platelet count <150×109/L, 21% vs 14%, P=.001) (Table 1). Concurrently, 
patients presenting at a younger age more often manifest an earlier disease stage, both 
biochemically and histologically, albeit with significantly greater serum transaminases and ALP 
values than older patients (P<.0001) (Table 2). The ALP levels in age groups 36-45 and 46-
55 were significantly lower from that of 56-65 and >65 (P<.001). Furthermore, there was 
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significantly higher ALP in the group 56-65 compared to the age group >65 (P=.001). Younger 
patients were more likely to present with an ALP>4×ULN: 27%, 31%, 27%, 18%, and 14%, in 
order from youngest to oldest (P<.001). 
 
Table 1. Baseline characteristics of the total cohort of PBC patients and according to sex  
     Parameter All patients                 n=4355 
Male                                                                           
n=446 
Female                                                                 
n=3909 P-value 
Age at beginning of follow-up, 
mmean±SD 
54.7 ± 11.7 58.3 ± 12.1 54.3 ± 11.6 <.0001 
AMA-positive, no. (%)a  3849 (90.7) 410 (92.8) 3439 (90.5) .12 
Year of diagnosis, no. (%) 
   
.44 
<1990 816 (18.7) 79 (17.7) 737 (18.9) 
 
1990-2000 1678 (38.5) 161 (36.1) 1517 (38.8) 
 
2000-2010 1655 (38.0) 181 (40.6) 1474 (37.7) 
 
>2010 206 (4.7) 25 (5.6) 181 (4.6) 
 
Biochemical disease stage, no. (%)b 
   
<.0001 
Early 1731 (67.9) 146 (52.9) 1585 (69.8) 
 
Moderate 618 (24.3) 91 (33.0) 527 (23.2) 
 
Advanced 199 (7.8) 39 (14.1) 160 (7.0) 
 
Histological disease stage, no. (%)c 
   
.84 
Early stage disease (F1-2) 1225 (68.3) 121 (67.6) 1104 (68.4) 
 
Late stage disease (F3-4) 569 (31.7) 58 (32.4) 511 (31.6) 
 
Portal hypertension, no. (%)d  368 (14.8) 59 (21.2) 309 (13.9) .001 
Laboratory parameters, median (IQR)e 
    
        AST (×ULN) 1.43 (0.94-2.23) 1.40 (0.92-2.13) 1.45 (0.94-2.23) .42 
        ALT (×ULN) 1.64 (1.00-2.60) 1.65 (1.00-2.61) 1.64 (1.00-2.60) .96 
        ALP (×ULN) 2.07 (1.30-3.71) 2.00 (1.30-3.40) 2.10 (1.30-3.74) .26 
        Albumin (×LLN) 1.14 (1.06-1.23) 1.14 (1.03-1.24) 1.14 (1.06-1.23) .05 
        Total bilirubin (×ULN) 0.65 (0.45-1.04) 0.82 (0.59-1.49) 0.62 (0.44-1.00) <.0001 
        Platelets (x109/L) 244 (186-297) 216 (162-262) 248 (190-300) <.0001 
PBC, primary biliary cholangitis; SD, standard deviation; AMA, anti-mitochondrial antibody; IQR, interquartile range; 
AST, aspartate aminotransferase; ULN, upper limit of normal; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; LLN, lower limit of normal 
a AMA status was unavailable for 112 patients (4 males, 108 females).  
b Biochemical disease stage defined as per ter Borg et al.14 (early: normal serum bilirubin and albumin levels, 
moderate: abnormal serum bilirubin or albumin levels, advanced: abnormal serum bilirubin and albumin levels). 
Insufficient data for determination in 41.5% (n=1807, all patients); 38.1% (n=170, males) and 41.9% (n=1637, 
females). 
c Baseline biopsy was performed in 51.5% (2244 patients; 232 males and 2012 females). Baseline histological 
disease stage was unavailable in 20.1% (n=450, all patients), 22.8% of male patients (n=53) and 19.7% of female 
patients (n=397).  
d Portal hypertension defined as a platelet count <150x109/L. Platelet count was available for 57.2% (2494 patients; 
278 males and 2216 females). 
e Due to differences in normal thresholds between centres, laboratory values are listed as factors of the upper and 
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Table 2. Baseline characteristics according to age at UDCA initiation  
 
Parameter <35                       n=199 
36-45                               
n=727 
46-55                      
n=1305 
56-65                      
n=1234 




Male sex 15 (7.5) 55 (7.6) 97 (7.4) 140 (11.3) 139 (15.6) <.0001 
AMA-positive  172 (87.8) 634 (90.7) 1139 (89.9) 1094 (90.6) 810 (92.8)  .11 
Diagnosis year      <.0001 
      <1990 28 (14.0) 112 (15.4) 239 (18.3) 268 (21.7) 169 (19.0)  
      1990-1999 64 (32.2) 330 (45.4) 530 (40.6) 460 (37.3) 294 (33.0)  
      2000-2010 101 (50.8) 259 (35.6) 482 (36.9) 444 (36.0) 369 (41.5)  
      >2010 6 (3.0) 26 (3.6) 54 (4.1) 62 (5.0) 58 (6.5)  
Biochemical 
Disease stagea 
      .003 
      Early 71 (67.6) 238 (63.1) 496 (69.5) 549 (71.6) 377 (64.4)  
      Moderate 30 (28.6) 116 (30.8) 164 (23.0) 159 (20.7) 149 (25.5)  
      Advanced 4 (3.8) 23 (6.1) 54 (7.6) 59 (7.7) 59 (10.1)  
Histological 
Disease stageb 
     .03 
      Early (F1-2) 74 (77.1) 250 (69.6) 443 (70.8) 288 (64.4) 170 (63.9)  
      Late (F3-4) 22 (22.9) 109 (30.4) 183 (29.2) 159 (35.6) 96 (36.1)  
Portal 
hypertensionc 8 (7.4) 29 (7.5) 81 (11.6) 117 (15.8) 133 (23.8) <.0001 
Laboratory values       
    AST (×ULN) 1.67 (1.03-2.75) 1.89 (1.15-2.80) 1.53 (1.00-2.40) 1.30 (0.90-2.00) 1.23 (0.83-1.87) <.0001 
ALT (×ULN) 2.25 (1.43-3.89) 2.46 (1.37-3.80) 1.87 (1.20-2.86) 1.49 (1.00-2.20) 1.20 (0.79-1.84) <.0001 
ALP (×ULN) 2.01 (1.12-4.22) 2.55 (1.49-4.83) 2.33 (1.45-4.13) 2.00 (1.30-3.31) 1.15 (1.20-2.76) <.0001 
Albumin (×LLN) 1.17 (1.09-1.27) 1.16 (1.06-1.25) 1.16 (1.08-1.26) 1.14 (1.06-1.24) 1.11 (1.01-1.20) <.0001 
Total bilirubin      
(×ULN) 0.64 (0.42-1.06) 0.71 (0.48-1.23) 0.60 (0.41-1.00) 0.67 (0.48-1.00) 0.67 (0.48-1.05)  .003 
 Platelet count 
(x109/L)  261 (224-302) 277 (222-331) 253 (202-304) 233 (177-284) 216 (151-272) <.0001 
 
UDCA, ursodeoxycholic acid; AMA, anti-mitochondrial antibody; IQR, interquartile range; AST, aspartate 
aminotransferase; ULN, upper limit of normal; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LLN, 
lower limit of normal.  
 All data presented as no. (%), expect laboratory values, which are expressed as median (IQR).  
a Biochemical disease stage defined as per ter Borg et al.14 - early: normal serum bilirubin and albumin levels, 
moderate: abnormal serum bilirubin or albumin levels, advanced: abnormal serum bilirubin and albumin levels. 
Insufficient data for determination in 41.5% (94, 350, 591, 467, and 305 for each age group). 
 b Baseline histological disease stage was not available in 23% (n=28), 21% (n=95), 15% (n=114), 23% 
(n=135), 23% (n=266) in each respective age group (listed from youngest to oldest). 
 c Portal hypertension defined as a platelet count <150x109/L. Platelet count was unavailable for 57.3% (91, 339, 
608, 493, 330 for each respective age group listed from youngest to oldest). 
 
Effect of age on biochemical response to ursodeoxycholic acid 
Across the cohort in its entirety, laboratory data after 1 year of UDCA therapy were available 
for 4200 patients (96%). On univariable analysis, older age at UDCA initiation was associated 
with higher likelihood of achieving biochemical response according to the GLOBE score (per 
10-year increase in age: OR 1.25, 95% CI 1.18-1.32, P<.0001). After adjusting for additional 
baseline factors, older patients appeared to have significantly better response than younger 
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patients (Table 3). The same relationship was observed when age was analyzed as a 
categorical variable in multivariable analysis: ≤45 years (reference group), 46-55 years (OR 
2.67, 95% CI 2.06-3.46, P<.0001), 56-65 years (OR 4.91, 95% CI 3.68-6.56 P<.0001), >65 
years (OR 5.48, 95% CI 3.92-7.67, P<.0001). When analyzing the effect of age on biochemical 
response to UDCA in male and female patients separately, age had a similar effect in both 
(Supplementary Figure 1). In independent multivariable logistic regressions, the OR per 10-
year increase in age was comparable for male and female patients (male: OR 1.65, 95% CI 
1.27-2.12, P<.001; female: OR 1.49, 95% CI 1.36-1.64, P<.001). Furthermore, the interaction 
term between age and sex was not significantly different (P=.66) and there was no evidence 
of an additive interaction. Age was also a significant predictor for the other response criteria 
except Rotterdam criteria (Supplementary Table 1). Older patients had a higher probability 
of response than younger patients, irrespective of whether their GLOBE score at baseline was 
below or above the age-specific thresholds (Figure 1). The effect of age was also assessed 
with a restricted cubic spline function, which suggested the positive effect of age is less 
pronounced after the age of 65 (P=.004) (Supplementary Figure 2). 
Because younger patients were more likely to have elevated ALT and AST levels, we assessed 
whether these biochemical markers were independently associated with response to UDCA in 
separate multivariable models while adjusting for center, sex, age, year of diagnosis, response 
at baseline and log bilirubin. AST but not ALT was an independent predictor of response (ALT 
[log]: OR 1.15, 95% CI 0.84-1.58, P=.39; AST [log]: OR 0.57, 95% CI 0.39-0.84, P=.004). 
Effect of sex on biochemical response to ursodeoxycholic acid 
Overall, male patients had significantly lower biochemical response compared to female 
patients (62% [n=263] vs 72% [n=2732], P<.0001) and male sex was associated with lower 
response (OR 0.62, 95% CI 0.50-0.76, P<.0001). However, after adjusting for parameters 
corresponding to disease severity (baseline bilirubin, ALP, albumin, and platelet count), age at 
UDCA initiation, year of diagnosis, GLOBE score status at baseline, and center, male sex was 
no longer an independent predictor of response (OR 0.77, 95% CI 0.57-1.04, P=.09) (Table 
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Table 3. Multivariable logistic regression for factors affecting biochemical response to UDCA 




Entire cohort (n=4200)  
OR       95% CI P-value 
Male sex 0.77 0.57-1.04 .09 
Age at UDCA initiation (per 10-year increase) 1.51 1.37-1.64 <.0001 
Year of diagnosis (per 10-year increase) 1.11 0.96-1.27 0.16 
Baseline log bilirubin (×ULN) 0.06 0.03-0.09 <.0001 
Baseline log ALP (×ULN) 0.28 0.19-0.40 <.0001 
Baseline albumin (×LLN) (per 0.5 increase) 3.75 2.57-5.49 <.0001 
Baseline platelet count (per 50×109/L increase)  1.49 1.42-1.57 <.0001 
GLOBE score below threshold at baseline  3.76 2.85-4.95 <.0001 
UDCA, ursodeoxycholic acid; OR, odds ratio; CI, confidence interval; ULN, upper limit of normal; ALP, 




Figure 1. Predicted probability of GLOBE response according to age at the start of 
ursodeoxycholic acid (UDCA) treatment stratified by GLOBE status at baseline. Predicted 
probability of GLOBE response according to age at UDCA initiation in (A) patients whose 
GLOBE score at baseline is below the age-specific threshold (n=2621) and (B) patients whose 
GLOBE score at baseline is above the age-specific threshold (n=1579). Predicted probabilities 
obtained from a logistic regression correspond to a PBC patient diagnosed in 2000 with median 
laboratory values after adjusting for diagnosis year, sex, bilirubin, albumin, and platelet count. 
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Transplant-free survival among different age groups 
The 10-year transplant-free survival rate decreased with age in the corresponding age groups 
from youngest to oldest: 89.4%, 87.0%, 82.4%, 77.7%, and 64.1% (P<.001). To gain additional 
insight into the effect of age on transplant-free survival of PBC patients, they were assessed 
relative to a general population (matched according to age, sex, and birth year) within each 
age group. On life table analysis, the PBC population within each age group had significantly 
lower transplant-free survival than the matched general population (Figure 2A). Interestingly, 
the transplant-free survival HR relative to a general population significantly decreased with 
advancing age (P<.0001) (Figure 2B). PBC patients who were ≤35 years old had the highest 
HR (HR 14.59, 95% CI 9.66-22.02, P<.0001) and patients >65 years of age had the lowest 
(HR 1.39, 95% CI 1.23-1.57, P<.0001). The distribution of clinical events from the 5-year 
transplant-free survival (n=67) was also significantly variable with age, because younger 
patients more often received a liver transplant and older patients experienced increased 
mortality that was primarily liver-unrelated (P<.0001) (Supplementary Figure 3A).  
Transplant-free survival among male and female patients 
On crude analysis of overall transplant-free survival, male patients had a significantly lower 
10-year transplant-free survival rate than female patients (67.7% vs 80.1%, P<.0001) 
(Supplementary Figure 4A). However, after adjusting for age at UDCA initiation, year of 
diagnosis, bilirubin, ALP, platelet count, and center, the increased risk for liver transplantation 
or death in male patients was no longer significant (HR 1.19, 95% CI 0.99-1.44, P=.07) (Table 
4, Supplementary Figure 4B). There was also no significant difference in the distribution of 
clinical events from the 5-year transplant-free survival between male and female patients 
(Supplementary Figure 3B).  
 
Table 4. Multivariable Cox regression for factors affecting transplant-free survival  
  
Baseline variable 
Entire cohort (n=4349) 
HR 95% CI P-value 
Male sex 1.19 0.99-1.44 .07 
Age at UDCA initiation (per 10-year increase) 1.55 1.47-1.66 <.0001 
Year of diagnosis (per 10-year increase) 0.83 0.75-0.92 .001 
Baseline log bilirubin (×ULN) 7.34 6.03-8.93 <.0001 
Baseline log ALP (×ULN) 1.88 1.47-2.40 <.0001 
Platelet count (per 50×109/L increase) 0.88 0.83-0.93 <.0001 
HR, hazard ratio; CI, confidence interval; ULN, upper limit of normal; ALP, alkaline phosphatase. 
 
4




Figure 2. Transplant-free survival according to age at the start of ursodeoxycholic acid (UDCA) 
of PBC patients compared with age-, sex-, and birth year-matched general population. (A) Life 
table analysis of transplant-free survival in different age groups relative to matched general 
population. (B) Transplant-free survival hazard ratios (95% CI) obtained from Cox regression 
analyses of PBC patients relative to matched general population and in different age groups. 
Age was a significant determinant of the transplant-free survival hazard ratio relative to 









The results of our study confirm that a younger age at presentation confers an impaired 
biochemical response to UDCA compared with older patients, even after adjusting for sex and 
disease severity. Despite manifesting less severe biochemical and histologic disease, younger 
patients exhibit more pronounced biochemical hepatitic activity, as evident by significantly 
greater serum transaminases levels.19 Moreover, younger age is also associated with 
markedly lower transplant-free survival relative to a matched general population. Conversely, 
patient sex does not appear to be an independent determinant of biochemical response or 
transplant-free survival, but rather, male patients present with more advanced disease, a 
known cause of diminished treatment response and prognosis in PBC.2,20  
Similar to other diseases of autoimmune origin, the pathogenesis of PBC appears to be driven 
by fundamental differences in susceptibility across male and female patients, as well as 
different age groups.  The inherent challenges posed by the epidemiology of PBC have led to 
an elusive understanding of whether male patients or younger patients have a more aggressive 
disease phenotype.  Owing to the size of the cohort and statistical validation through the use 
of center-specific stratification and multiple imputation, our study is strongly positioned to 
explore outcomes in small subgroups while minimizing bias.   
In line with our study’s findings, Carbone et al. found that when response was stratified by sex, 
it appeared that older female patients have significantly better response than their younger 
counterparts, whereas male patients have weak age-associated response rates.7 However, 
we found that the effect of age on response to UDCA is similar in both sexes. There are several 
potential reasons for lower rates of biochemical response in younger patients. Although the 
relationship between age and medication compliance is complex, one possibility is that 
younger patients have reduced compliance, as demonstrated in other chronic disease 
literature.21,22 Alternatively, disparities in response may be related to underlying disease 
pathology. Patients with ductopenia have been previously demonstrated to have diminished 
response to UDCA23, and descriptions of a severe ductopenic variant of PBC all involved 
patients younger than 50 years of age.24 Younger patients were more likely to present with 
severe disease, as determined by ALP levels above 4×ULN and thus it is possible that they 
also have a predominantly ductopenic phenotype that is particularly resistant to UDCA 
treatment. In addition, patients in our cohort younger than the age of 45 appeared to have 
higher AST and ALT, which may suggest more exuberant histologic inflammation. 
Interestingly, Carbone et al. found that younger patients were more likely to fail therapy based 
on transaminase criteria7, which collectively implies a more hepatitic phenotype. Alternatively, 
it may reflect a more advanced disease because of the association of AST elevations with 
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cirrhosis. Indeed, AST was an independent predictor of response in our cohort. Furthermore, 
we demonstrate that the effect of age on response rates does not vary according to their status 
at baseline (criteria for response evaluated at baseline).  
The life expectancy of asymptomatic patients diagnosed at 55 years or older has been shown 
to be comparable with a matched population.25 Similarly, we found that when our cohort of 
PBC patients was matched to a general population, the risk for liver transplantation and death 
incrementally decreased with increasing age. Taking into account that younger patients are 
less likely to respond to UDCA, this suggests that younger patients could have lower 
transplant-free survival than their older counterparts as a consequence of diminished treatment 
response.  
Earlier studies have demonstrated that male patients present with more advanced disease, 
reflected by their higher rates of jaundice, variceal bleeding, and thrombocytopenia at 
presentation.5,7 Asymptomatic male patients also present at an older age than female patients, 
with a mean difference of approximately 5 years.5,7  The UK-PBC cohort also showed that male 
sex was an independent predictor of biochemical response. In contrast, our study 
demonstrated that sex was not independently associated with biochemical response or 
transplant-free survival. In a previous study of a Dutch population, sex was also not an 
independent predictor of response to UDCA.26 The lack of association between male sex and 
clinical outcomes in PBC suggests that sex is not an inherent determinant of treatment 
response or prognosis, but rather that males are at greater risk of presenting with more 
advanced disease, with a greater degree of hepatic synthetic dysfunction and portal 
hypertension. A possible factor to explain this finding is that the diagnosis of PBC is not 
sufficiently considered in male patients presenting with features of liver disease. However, this 
is highly speculative, and it may well be that male patients develop less frequent or less severe 
symptoms and therefore remain undiagnosed until later in the course of the disease. Lastly, 
although this is the largest study of the impact of male sex on transplant-free survival, it is 
possible that we were insufficiently powered to detect a small effect size. This would suggest 
that despite adequate biochemical response, additional factors are leading to decreased 
transplant-free survival in male patients. This highlights the need for further research 
evaluating sex-specific factors in the outcome of PBC patients, both from an epidemiologic 
standpoint as well as clinical trials. 
In conclusion, patient age irrespective of sex has significant impact on biochemical response 
and transplant-free survival. Our data suggest that younger patients should be monitored 
carefully, with early consideration for additional therapies, because they appear to be at 
greatest risk of biochemical non-response to UDCA, liver transplantation, and death. The 
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presence of more overt biochemical hepatitic activity suggests a more aggressive and 
inflammatory phenotype in younger compared with older patients. Conversely, males appear 
to be diagnosed at a more advanced disease stage, putatively accounting for the differences 
in biochemical response rates compared with female patients. It is thus important to prevent 
diagnostic delays by maintaining a high index of suspicion for PBC in male patients and 
aggressively managing any potential concomitant causes of progressive fibrosis. Further 
studies are required to unravel the mechanisms underlying the diminished treatment response 
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Supplementary Figure 1. The impact of age on response to UDCA according to GLOBE score 
stratified by sex.  
 
 
Supplementary Table 1. Multivariable logistic regression of the effect of age on biochemical 
response to UDCA according to various published criteria  
Criteria ORa 95% CI P-value 
Barcelona 1.12 1.05-1.18 <.0001 
Paris-I 1.15 1.06-1.23 .001 
Rotterdam 0.94 0.88-1.02 .14 
Toronto 1.25 1.16-1.34 <.0001 
Paris-II 1.15 1.08-1.23 <.0001 
UDCA, ursodeoxycholic acid; OR, Odds ratio; CI, confidence interval.  
a OR corresponds to a 10-year increase in age. 
 
 
Supplementary Table 2. Multivariable logistic regression of the effect of sex on  biochemical 
response to UDCA according to various published criteria  
Criteria ORa  95% CI P-value 
Barcelona 1.05 0.84-1.31 .66 
Paris-I 0.88 0.66-1.16 .35 
Rotterdam 0.80 0.61-1.05 .10 
Toronto 0.80 0.60-1.05 .10 
Paris-II 1.06 0.82-1.37 .67 
UDCA, ursodeoxycholic acid; OR, Odds ratio; CI, confidence interval. 
a OR corresponds to male sex. 
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Supplementary Figure 2. The association between age and the odds for response to UDCA 
according to the GLOBE score modelled by a restricted cubic spline function. The age 




Supplementary Figure 3. The distribution of clinical events at 5 years stratified by age at the 
start of ursodeoxycholic acid and sex. The distribution of liver-unrelated death, liver-related 
death, and liver transplantations at 5 years (n=67) according to (A) age at the start of 










Supplementary Figure 4. Crude and adjusted transplant-free survival curves of males and 
females. Survival curves of (A) unadjusted (crude) transplant-free survival and (B) adjusted 
transplant-free survival between males and females. Cox regression analysis (n=4349) was 
adjusted for center, age at the start of ursodeoxycholic acid, year of diagnosis, serum 
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Background: Fibrosis stage predicts prognosis in patients with chronic liver disease 
independent of disease aetiology, although its precise role in risk stratification in patients with 
primary biliary cholangitis (PBC) remains undefined.  
Aims: To assess the utility of baseline fibrosis stage in predicting long-term outcomes in the 
context of biochemical risk stratification. 
Methods: In a large and globally representative cohort of patients with PBC, liver biopsies 
performed from 1980 to 2014 were evaluated. The predictive ability of histologic fibrosis stage 
in addition to treatment response at 1 year (Toronto/Paris-II criteria), as well as non-invasive 
markers of fibrosis (AST/ALT ratio [AAR], AST to platelet ratio index [APRI], FIB-4), for 
transplant-free survival was assessed with Cox proportional-hazards models.   
Results: There were 1828 patients with baseline liver biopsy. Advanced histologic fibrosis 
(stage 3/4) was an independent predictor of survival in addition to non-invasive measures of 
fibrosis with the hazard ratios ranging from 1.59-2.73 (P<0.001). Patients with advanced 
histologic fibrosis stage had worse survival despite biochemical treatment response, with a 10-
year survival of 76.0-86.6% compared to 94.5-95.1% depending on the treatment response 
criteria used. Poor correlations were observed between non-invasive measures of fibrosis and 
histologic fibrosis stage.  
Conclusion: Assessment of fibrosis stage grants prognostic value beyond biochemical 
treatment response at 1 year. This highlights the need to incorporate fibrosis stage in individual 








Primary biliary cholangitis (PBC) is a chronic autoimmune biliary disease characterized by 
immune-mediated destruction of intrahepatic bile ducts, cholestasis, portal inflammation and 
over time, a progression to end-stage biliary cirrhosis. While the histologic features can serve 
as diagnostic parameters, for the majority of patients, in keeping with consensus treatment 
guidelines, diagnosis is made based on the co-incidence of cholestatic serum liver tests and 
specific anti-mitochondrial antibodies. This has meant the utility of routine baseline biopsy for 
patients living with PBC has been questioned; yet liver biopsy findings, beyond diagnosis, may 
be of value in determining the risk of end-stage liver disease complications, by the 
understanding offered from directly evaluating stage of liver fibrosis at presentation. Yet 
relatively little formal evaluation exists exploring how the information gained from a baseline 
liver biopsy in PBC as regards to histologic stage, can contribute to long-term risk stratification 
for individual patients. While on its own, advanced histologic stage is an independent predictive 
factor for transplant-free survival conferring a 1.5-fold increased risk for liver transplantation or 
death,1,2 less is known of its utility in the context of biochemical risk tools; and by extension, 
the value baseline liver fibrosis stage may offer for refining timely adoption of therapies 
designed to optimize outcomes of patients.1,3–6 
In PBC, most laboratory tools designed to allow clinical risk stratification rely on biochemical 
markers, including treatment response to first-line therapy with ursodeoxycholic acid (UDCA). 
Bilirubin and alkaline phosphatase (ALP) are surrogate markers that, either in binary, or as 
part of continuous models, predict outcome including transplant-free survival in patients with 
PBC.7,8 Several easily measurable non-invasive markers of fibrosis (AST/ALT ratio [AAR], AST 
to platelet ratio index [APRI], and FIB-4) have also been described,5,9,10 and while they were 
initially developed and validated in patients with chronic viral hepatitis, their utility in fibrosis 
assessment and prediction of prognosis in PBC has also been suggested.5  
Using the large dataset afforded by the Global PBC Study Group, for which long-term outcome 
is reported, as well as comprehensive biochemical stratifiers, we sought to robustly explore 
the utility for patients offered by understanding at baseline the stage of liver fibrosis.  To do so, 
we characterized histologic fibrosis stage in a large international cohort of PBC patients; 
determined whether histologic fibrosis staging improves risk stratification in addition to, and 
independently of, biochemical non-invasive measures of fibrosis and biochemical treatment 
response; evaluated the correlation between histology and biochemical non-invasive markers 
of fibrosis; and established optimal PBC-specific thresholds of non-invasive markers of fibrosis.  
  




Population and study design  
Data from the GLOBAL PBC Study Group database, an international cohort of patients with 
PBC from Europe and North America was used for this study. We included UDCA-treated 
patients diagnosed with PBC according to established criteria in whom a liver biopsy was 
performed at study entry.11 Biopsies conducted in the 24 months prior to study entry and up to 
12 months after study entry were considered as baseline in order to maximize the number of 
eligible patients while minimizing selection bias that may already exist in those who are 
biopsied. These criteria were employed given established supportive data demonstrating that 
short-term treatment with UDCA is not associated with regression of histologic stage.12,13 A 
sub-analysis limited to patients with biopsies 6 months prior to UDCA initiation but not after, 
was also performed. Patients with a short follow-up (<6 months), UDCA discontinuation, 
unknown dates of clinical events, autoimmune hepatitis overlap syndrome, or another 
concomitant liver disease were excluded from the study. Patients with a biopsy outside the 
specified time frames were also excluded. This study was conducted in accordance with the 
1975 Declaration of Helsinki. The protocol was approved by the institutional research board at 
all participating centers as per local regulations. 
Data collection  
Baseline (study entry) was defined as the date of UDCA initiation. At study entry, the following 
data were collected: sex, age at diagnosis, anti-mitochondrial (AMA) antibody serological 
status, biochemical disease stage according to Rotterdam criteria14, and histologic stage, for 
which the most commonly used methods for staging were Ludwig and Scheuer’s criteria.15,16 
Given the variability in staging systems used across centers, for the purposes of this study 
patients were categorized as having early fibrosis stage if reported as having stage 1 or 2 
disease and advanced fibrosis stage if reported as having stage 3 or 4 disease or evidence for 
cirrhosis. The following laboratory parameters were collected every 6-12 months: total bilirubin, 
ALP, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet 
count.  
Statistical Analyses  
The primary endpoint was a composite of liver transplantation and death. The influence of the 
various measures of fibrosis on transplant-free survival were assessed with multivariable Cox 
proportional hazards’ regressions (hazard ratio [HR] with 95% confidence interval [CI]) while 
adjusting for age at the start of UDCA, sex, center, and year of diagnosis. In order to determine 
whether histologic fibrosis stage confers additional prognostic information to the non-invasive 
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markers of fibrosis, histologic fibrosis stage≥3 was inputted into the model in a forward step 
approach. The impact of histologic fibrosis stage was assessed as stage 1/2 vs stage 3/4 due 
to potential sampling and interpretative errors associated with liver biopsy. Furthermore, given 
that the non-invasive tests are used as measures of fibrosis, we aimed to limit the discussion 
to fibrosis stage.  Each non-invasive marker was evaluated as a continuous and dichotomous 
variable according to established thresholds that have been associated with advanced 
fibrosis/cirrhosis (AAR=1, APRI=2, and FIB-4=3.25),17 with the GLOBE score analysed based 
on age-specific thresholds.7 Additionally, thresholds established based on the Youden index 
in our cohort were also employed. APRI and FIB-4 were not normally distributed and thus were 
log transformed (natural logarithm [LN]) for all analyses. For elaborative purposes, the 
components of each non-invasive marker were evaluated independently to determine which 
component grants the highest predictive value for transplant-free survival, as determined by 
the concordance statistics (C-statistics). 
In order to assess the prognostic impact of baseline histologic fibrosis stage in the context of 
biochemical response after 1 year of UDCA therapy, patients were stratified based on 
histologic fibrosis stage (early vs advanced fibrosis) and treatment response defined by 
Toronto (ALP≤1.67× upper limit of normal [ULN])18 and Paris-II criteria (ALP≤1.5×ULN, 
AST≤1.5×ULN, and normal bilirubin)19 to estimate their survival with a Kaplan-Meier curve. 
These criteria were employed because they are the most widely used to determine response 
to UDCA, including in clinical trials.18,20 Advanced fibrosis was defined as stage≥3 and 
according to the thresholds of the non-invasive markers of fibrosis (AAR/APRI/ FIB4) 
established with the Youden index. A Cox regression analysis was employed to estimate the 
HR associated with these categories. Subsequently, we aimed to determine whether 
differences exist in ability to predict transplant-free survival based on methods of fibrosis 
assessment (histologic fibrosis stage, AAR, APRI, or FIB-4) while considering treatment 
response 1 year.  
Non-invasive markers of fibrosis, namely AAR, APRI, and FIB-4, were calculated at baseline. 
The diagnostic performance of these markers for the diagnosis of histologic fibrosis stage ≥2, 
stage≥3, and stage=4 was assessed with a receiver operating curve. Additionally, the potential 
correlation between Rotterdam biochemical disease stage and the GLOBE score with 
histologic fibrosis stage was also assessed. A grid search of the area under the receiver 
operating curve (AUROC) was also used to establish disease-specific thresholds for APRI and 
FIB-4 with a 95% sensitivity and 95% specificity for the diagnosis of cirrhosis. The negative 
predictive value (NPV) and positive predictive value (PPV) of the conventional thresholds and 
newly determined thresholds for cirrhosis were calculated.17 Conventional thresholds of FIB-4 
to exclude advanced fibrosis, namely FIB-4≤1.45, and to rule in advanced fibrosis, FIB-4>3.25, 
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were used.17 Additionally, the threshold with the highest sensitivity and specificity for the 
diagnosis of advanced fibrosis (stage≥3) was determined with the Youden index (J) for each 
non-invasive marker of fibrosis.  
Multiple imputation was completed by the Markov Chain Monte Carlo (MCMC) method for 
missing data with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Ten imputed data sets 
for missing biochemical values were generated to reduce sampling variability of laboratory 
results at baseline and yearly thereafter up to 15 years (SAS Proc MI, MCMC method).21 The 
imputation was performed based on the assumption that data were missing at random, in which 
variables predicting outcomes and outcomes themselves were included in the imputation 
model. Rubin’s rules were used to estimate the parameter and standard error.22,23  
A P-value of < 0.05 was considered statistically significant. All analyses were two-sided and 
were performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, 
NY, USA) and SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
RESULTS  
Study population characteristics 
A total of 1828 patients with a liver biopsy with assessment of histologic fibrosis stage at 
baseline were included, whose baseline characteristics are reported in Table 1. The majority 
of biopsies were conducted within 6 months of study entry (n=1496, 81.8%). Within the cohort, 
66.9% (n=1223) had early histologic fibrosis stage (stage 1 or 2) and 33.1% (n=605) had 
advanced histologic fibrosis stage (stage 3 or 4). The median follow-up time was 8.4 years 
(4.9-12.4). The primary endpoint was met in 310 patients (194 deaths and 116 liver 
transplantations). The biopsies in this study were performed from 1980 to 2014, and reflective 
of practice, with a bias towards 1993 to 2004. Due to the unknown indications for the biopsies 
performed, the characteristics of patients included in this study were compared to those without 
a biopsy to examine a potential selection bias. Patients with a biopsy were younger and had 
significantly higher ALP, bilirubin, AST, and ALT, but similar albumin (Supplementary Table 
1). While the 10-year transplant-free survival was higher for those biopsied (84.3%) compared 
to those not biopsied (73.8%) (Supplementary Figure 1), an absence of biopsy was not a 
significant predictor of outcome in multivariable analysis when considering age, sex, year of 
diagnosis, UDCA treatment, and center (HR 1.03, 95% CI 0.76-1.40, P=0.85). Response rates 
between the biopsied group and the non-biopsied group were similar (Supplementary Table 
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SD, standard deviation; UDCA, ursodeoxycholic acid; AMA, antimitochondrial antibody; ULN, upper limit of 
normal; ALP, alkaline phosphatase; LLN, lower limit of normal; AST, alanine amminotransferase; ALT, 
alanine aminotransferase. 
 
†Biochemical disease stage according to Rotterdam criteria14 was available for 1014 (55.5%) patients.  
‡Laboratory parameters were not available for all patients: Total bilirubin (n=1305, 71.4%), ALP (n=1370, 
74.9%), albumin (n=1057, 57.8%), AST (n=1336, 73.1%), ALT (n=1330, 72.8%), platelet count (n=1098, 
60.1%). 
 
Histologic fibrosis stage is an independent predictor of transplant-free survival  
We sought to confirm that assessment of fibrosis stage histologically and/or by non-invasive 
testing predicts outcome. Analyses of histology were limited to stage 1/2 vs stage 3/4, but 
incremental changes in disease stage were associated with prognosis (Figure 1A). The 
transplant-free survival at 10 years of patients with early histologic fibrosis stage was 
significantly improved to those with advanced stage, 91.8% vs 70.2% (P<0.001; Figure 1). On 
multivariable analysis, fibrosis stage histologically and as assessed by non-invasive markers 
were significantly associated with outcome with advanced histologic fibrosis stage and 
increased biochemical non-invasive scores being associated with an increased risk for liver 
transplantation or death (Table 2). Each of the non-invasive measures independently predicted 
outcome but of the ones assessed, the Rotterdam criteria was the strongest predictor of 
outcome (C statistic 0.78, 95% CI 0.74-0.81), followed by FIB-4 (C statistic 0.75, 95% CI 0.72-
0.78), APRI (C statistic 0.71, 95% CI 0.68-0.75), and finally AAR (C statistic 0.69, 95% CI 0.65-
0.72). The laboratory parameter that was most predictive of survival for Rotterdam criteria, 
Baseline characteristics Total (n=1828) 
Age at study entry, mean (SD) 52.4 (11.3) 
Female, n (%) 1649 (90.2) 
AMA-positive, n (%) 1586/1761 (90.1) 
Year of diagnosis, median (P25-75)  1998 (1993-2004) 
Year of biopsy, median (P25-75) 1997 (1993-2003) 
Histologic stage, n (%)  
     1 649 (35.5) 
     2 574 (31.4) 
     3 289 (15.8) 
     4 316 (17.3) 
Biochemical disease stage†, n (%)  
     Early 728 (71.8) 
     Moderately advanced 234 (23.1) 
    Advanced 52 (5.1) 
Laboratory parameters‡, median (P25-75)  
     Total bilirubin, ×ULN  0.59 (0.43-0.91) 
     ALP, ×ULN  2.12 (1.34-3.83) 
     Albumin, ×LLN  1.16 (1.06-1.26) 
     AST, ×ULN  1.52 (1.06-2.32) 
     ALT, ×ULN  1.72 (1.09-2.70) 
     Platelet count, ×109/L  253 (204-300) 
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APRI, FIB-4, and AAR were bilirubin, platelet count, platelet count, and AST respectively. For 
reference, the C statistic for histologic stage 1/2 vs 3/4 was 0.72 (95% CI 0.69-0.75). 
In order to assess whether histologic fibrosis stage offers prognostic value beyond that gained 
from non-invasive markers of fibrosis, histologic fibrosis stage≥3 was included in a forward 
step approach. Histologic fibrosis stage was included in each model and was an independent 
significant predictor of transplant-free survival, irrespective of the non-invasive markers of 
fibrosis used as continuous or categorical variables (Table 2, Supplementary Table 2). The 
prognostic value of non-invasive markers of fibrosis (FIB-4 and APRI) in addition to response 



















Figure 1. Transplant-free survival estimates according to baseline histology stratified by A) 
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Table 2. Multivariable Cox regression models that depict the independent association of 
baseline histologic fibrosis stage and non-invasive markers of fibrosis with transplant-free 
survival 
  
 Multivariable† Multivariable (histologic fibrosis stage) ‡ 
 HR (95% CI) P value  HR (95% CI) P value 
Histologic 
fibrosis stage  
     
     Stage 1/2 1.00  - - - 
     Stage 3/4 2.85 (2.22-3.67) <0.001 - - - 
AAR  1.39 (1.25-1.54) <0.001 
AAR  1.34 (1.20-1.50) <0.001 
Stage 3/4 2.73 (2.12-3.51) <0.001 
APRI (LN)  2.39 (2.00-2.86) <0.001 
APRI (LN) 2.11 (1.75-2.53) <0.001 
Stage 3/4 2.07 (1.59-2.70) <0.001 
FIB-4 (LN) 3.19 (2.58-3.95) <0.001 
FIB-4 (LN) 2.76 (2.20-3.47) <0.001 
Stage 3/4 1.96 (1.50-2.56) <0.001 
GLOBE score 2.85 (2.48-3.27) <0.001 
GLOBE score 2.68 (2.31-3.11) <0.001 
Stage 3/4 1.59 (1.21-2.10) 0.001 
Rotterdam 
criteria  
  Rotterdam 
criteria 
  
     Mild 1.00       Mild 1.00  
     Moderate 3.66 (2.73-4.89) <0.001      Moderate 3.17 (2.36-4.26) <0.001 
     Advanced 10.98 (7.09-17.00) <0.001      Advanced 9.40 (6.00-14.72) <0.001 
   Stage 3/4 2.06 (1.57-2.69) <0.001 
HR, hazard ratio; CI, confidence interval; AAR, AST to ALT ratio; APRI, AST to platelet ratio index.  
 
†Adjusted for age at the start of follow-up, sex, year of diagnosis, and center.  
‡Adjusted for age at the start of follow-up, sex, year of diagnosis, and center. Histologic fibrosis stage (3/4 





Table 3. Multivariable Cox regression models that depict the combined association of 
response to treatment after 1 year and baseline histologic fibrosis stage with transplant-free 
survival 
 
Group  HR (95% CI) † P value 
Toronto criteria‡   
Response + stage 1/2 1.00  
Non-response + stage 1/2 2.94 (1.97-4.40) <0.001 
Response + stage 3/4 3.08 (2.09-4.53) <0.001 
Non-response + stage 3/4 6.29 (4.37-9.04) <0.001 
Paris-II criteria§   
Response + stage 1/2 1.00  
Non-response + stage 1/2 2.98 (1.95-4.55) <0.001 
Response + stage 3/4 2.17 (1.29-3.64) 0.003 
Nonresponse + stage 3/4 7.59 (5.14-11.22) <0.001 
HR, hazard ratio; CI, confidence interval. 
 
†Multivariable model also adjusted for age the start of follow-up, sex, year of diagnosis, and center. 
‡Response defined as ALP≤1.67×ULN. 
§Response defined as ALP≤1.5×ULN, AST≤1.5×ULN, and normal bilirubin. 
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Histologic fibrosis stage predicts prognosis despite biochemical treatment response 
The prognostic impact rendered by baseline fibrosis stage was assessed in addition to 
biochemical treatment response to UDCA according to Toronto and Paris-II criteria at 1year. 
Patients with advanced histologic fibrosis stage had a worse transplant-free survival despite 
treatment response, with a 10-year survival of 76.0% as compared to 94.5% according to 
Toronto criteria and 86.6% as compared to 95.1% for Paris-II criteria (Figure 2). Even with 
response defined as ALP normalization, patients with advanced histologic stage and normal 
ALP have worse transplant-free survival compared to those with early histologic stage and 
normal ALP (P<0.001), yet similar to those with early histologic stage and abnormal ALP 
(P=0.12), (Supplementary Figure 2). Furthermore, outcomes of patients with advanced 
histologic stage and normal ALP were also worse than those with early fibrosis and treatment 









Figure 2. Transplant-free survival estimates after 1 year of treatment with ursodeoxycholic 
acid stratified by baseline histologic fibrosis stage and biochemical response according to A) 
Toronto criteria and B) Paris-II criteria. In patients with complete response after 1 year, those 
with early histologic stage have worse survival as compared to those with advanced histologic 
stage. 
In multivariable analysis, a similar trend was noted (Table 3). All pairwise comparisons were 
statistically significant (P<0.01), except the risk in patients with incomplete treatment response 
and early histologic fibrosis stage compared to those with adequate treatment response and 
advanced histologic fibrosis stage (Toronto: P=0.82; Paris-II: P=0.18).  
The thresholds for AAR, APRI, and FIB-4 with the greatest sensitivity and specificity in the 
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(J=0.27), and 1.8 (J=0.29), respectively. A similar trend in outcomes was observed with 
Toronto criteria when advanced fibrosis was defined with these thresholds (Supplementary 
Table 4). The association of baseline histologic fibrosis stage with transplant-free survival was 
maintained after adjusting for ALP and AAR/APRI/FIB-4 at 1 year (Supplementary Table 5).   
The method of assessment of fibrosis at baseline that was most predictive of outcome in 
addition to treatment response at 1 year was assessed. This revealed that assessment of 
fibrosis stage using FIB-4 in addition to biochemical response after 1 year of UDCA therapy 
was most predictive of transplant-free survival (Toronto: C statistic 0.78, 95% CI 0.75-0.80; 
Paris-II: C statistic 0.78, 95% CI 0.75-0.81).  However, it was not significantly different from the 
other means of assessing fibrosis (histologic fibrosis stage, APRI, and AAR), suggesting all 
are similarly predictive of prognosis.  
The distribution of events (liver transplantation, liver-related death, or liver-unrelated death) 
according to biochemical response and histologic stage were significantly different between 
these groups (Supplementary Figure 3). The proportion of events that were liver-related (liver 
transplantation or liver-related death) was higher in those with an advanced histologic 
compared to those with an early histologic stage, irrespective of response status. The 
predominance of liver-related events in patients with advanced histologic stage, even 
responders, further supports the importance of assessing histologic fibrosis stage in the 
context of biochemical response and importantly, further emphasizes that this population 
remains at risk for clinically relevant liver-related endpoints.  
 
Biochemical non-invasive markers correlate poorly with histologic fibrosis stage in 
PBC  
Correlation between biochemical markers of fibrosis and histologic fibrosis stage was 
assessed by the AUROC for stage≥2, stage≥3, and stage=4 for AAR, APRI, FIB-4, Rotterdam 
disease stage, and GLOBE score, which are shown in Table 4. None of the biochemical non-
invasive measures of fibrosis evaluated demonstrated strong correlation with histologic fibrosis 
stage, although among those assessed, FIB-4, APRI, and GLOBE score showed the greatest 
correlation. The correlations between histologic fibrosis stage and non-invasive measures of 
fibrosis were lower than previously reported in the literature. When the cohort was restricted 
to only patients with biopsies conducted in the 6 months prior to, but not after UDCA initiation, 
similar findings were observed for the correlation between histologic fibrosis stage and non-
invasive markers, as well as the survival associated with patients with advanced histologic 
stage and complete response to UDCA (Supplementary Table 6, Supplementary Figure 4). 
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Table 3. Multivariable Cox regression models that depict the combined association of 
response to treatment after 1 year and baseline histologic fibrosis stage with transplant-free 
survival 
 
Group  HR (95% CI) † P value 
Toronto criteria‡   
Response + stage 1/2 1.00  
Non-response + stage 1/2 2.94 (1.97-4.40) <0.001 
Response + stage 3/4 3.08 (2.09-4.53) <0.001 
Non-response + stage 3/4 6.29 (4.37-9.04) <0.001 
Paris-II criteria§   
Response + stage 1/2 1.00  
Non-response + stage 1/2 2.98 (1.95-4.55) <0.001 
Response + stage 3/4 2.17 (1.29-3.64) 0.003 
Nonresponse + stage 3/4 7.59 (5.14-11.22) <0.001 
HR, hazard ratio; CI, confidence interval. 
 
†Multivariable model also adjusted for age the start of follow-up, sex, year of diagnosis, and center. 
‡Response defined as ALP≤1.67×ULN. 
§Response defined as ALP≤1.5×ULN, AST≤1.5×ULN, and normal bilirubin. 
 
Table 4. The area under the curve for the diagnosis of histologic fibrosis stage ≥ 3 and stage 
= 4 of various biochemical non-invasive markers in our cohort 
  
  AUROC (95% CI) 
Non-invasive marker Stage ≥ 2 
(n=1828) 
Stage ≥ 3 
(n=1828) 
Stage = 4 
(n=1828) 
AAR 0.54 (0.51-0.57) 0.60 (0.57-0.64) 0.63 (0.59-0.67) 
APRI 0.64 (0.61-0.67) 0.68 (0.65-0.71) 0.69 (0.65-0.72) 
FIB-4 0.64 (0.61-0.67) 0.69 (0.67-0.72) 0.73 (0.69-0.76) 
Rotterdam criteria 0.61 (0.58-0.64) 0.63 (0.61-0.66) 0.65 (0.61-0.68) 
GLOBE score  0.66 (0.63-0.69) 0.70 (0.67-0.73) 0.70 (0.66-0.74) 
AUROC, area under receiver operating curve; CI, confidence interval; AAR, AST to ALT ratio; APRI, AST to 
platelet ratio index.  
 
Optimal thresholds for AAR, APRI, and FIB-4 for prediction of cirrhosis in PBC 
patients 
The thresholds with 95% sensitivity in excluding cirrhosis (stage 4) for APRI and FIB-4 
established in our cohort were 0.26 and 0.70, respectively, which were lower than the 
conventional thresholds (Supplementary Table 7). The conventional thresholds to ‘rule out’ 
advanced fibrosis/cirrhosis demonstrated low sensitivity but NPV was approximately 90% 
(Supplementary Table 7). Meanwhile, the thresholds with 95% specificity for APRI and FIB-
4 were 2.00 and 4.03, respectively. As for APRI, the threshold developed in our cohort was 
equal to the conventional threshold (2.0); whereas the FIB-4 threshold developed in our cohort 
was higher and demonstrated improved specificity and PPV compared to the conventional 
threshold of 3.25. Although these thresholds are highly sensitive and specific, cirrhosis could 
only be excluded or included in a small proportion of patients from the total cohort (7-10%).  
5




In PBC there remain challenges for patients and clinicians as regards the best approaches to 
understanding the disease course, the risk of adverse events, and identification of those 
patients who will get the maximum benefit from disease modifying therapies.24 We sought to 
understand how baseline liver fibrosis stage could contribute to our understanding of PBC risk.  
We demonstrate that histologic fibrosis stage categorized as early (stage 1/2)  vs. advanced 
(stage 3/4) fibrosis is an independent predictor of transplant-free survival while adjusting for 
the non-invasive markers, and importantly, that its association with outcome persists after 1 
year, despite treatment response, that is, it adds prognostic information to a group with 
biochemical response to first-line treatment, potentially not presently readily identified. We 
further show that histologic fibrosis stage correlates poorly with biochemical non-invasive 
measures of fibrosis, namely FIB-4, APRI, and AAR; we finally establish disease-specific 
thresholds for cirrhosis for APRI and FIB-4. 
Despite poor correlation, both histologic fibrosis stage and non-invasive markers of fibrosis 
were independently predictive of patient outcome suggesting that each measure captures in 
different ways relevant context about disease biology, be it fibrosis, cholestasis (bilirubin), 
inflammation in addition to fibrosis (AST), and/or portal hypertension (platelet count).  
Nevertheless, while there are now other modalities such as elastography that have clinical 
utility beyond biopsy, it is telling that our data robustly demonstrates how the assessment of 
fibrosis stage at baseline, by histology as well as by biochemical non-invasive measures of 
fibrosis, predicts prognosis independent of UDCA treatment response after 1 year. In choosing 
the time point for second-line therapies this raises the question of when, and for whom, to add 
second-line therapy. Our data identified patients with advanced histologic fibrosis stage at 
baseline as having ongoing poor outcome despite biochemical treatment response and 
interestingly similar outcomes to those patients with inadequate biochemical response with 
early fibrosis – both groups demonstrating 9-19% lower 10-year transplant-free survival as 
compared to patients with early fibrosis and complete response. Similar findings were seen in 
a smaller series of 342 patients when response was assessed according to Toronto criteria 
after 2 years, yet the 10-year survival difference was 4% and 13%, with the greater difference 
in those with adequate response and advanced fibrosis stage. 6 Importantly, the need for 
second-line therapies is currently largely based on an assessment of biochemical response 
after 1 year of therapy with UDCA and does not incorporate an understanding of fibrosis stage 
in risk assessment. Our findings support the use of fibrosis stage histologically (only if clinically 
indicated) or by non-invasive means, in addition to the current biochemical criteria to identify a 
less readily recognized cohort at risk of impactful outcomes. Implementation can help identify 
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additional patients who may benefit from second-line therapies, namely biochemical 
responders that have an advanced fibrosis stage. 
Our findings emphasize that while biochemical markers of cholestasis are important in risk 
stratification, determining fibrosis stage histologically, or arguably now via non-invasive 
measures that are increasingly available including tools such as vibration controlled transient 
elastography (VCTE), must also be considered in the risk stratification of patients with PBC.25,26 
VCTE has shown strong correlation with advanced fibrosis stage in contemporary cohorts of 
patients PBC, though this data were not available in our cohort and were not readily available 
in many centers at the time of baseline liver biopsy. Additionally, although the access to 
elastography has increased significantly with time, it is still not a universally applicable tool for 
all patients. Although not part of our study, clear ongoing efforts to evaluate elastography in 
the management of patients with PBC are of clinical interest. Further, while liver biopsy at 
baseline is clinically logical, the timing of elastography as a surrogate is challenged by the 
combined effects of fibrosis and cholestasis on liver stiffness. While identification of patients 
with advanced stage disease is clearly important, there requires further study to understand 
whether new licenced therapies such as obeticholic acid or alternative off-label agents 
including bezafibrate, offer the same benefit to this subgroup with potentially normal (or near-
normal) ALP values.20,27  
Similar to prior smaller series,28 our large cohort study confirmed suboptimal correlation 
between histologic fibrosis stage and non-invasive markers. These correlations are weaker 
than previously described, which may be explained by our large sample size, differences in 
fibrosis staging systems used between studies, or differences in patient cohorts included, with 
some prior reports including patients with PBC-AIH overlap syndrome, prolonged UDCA use 
(6.9 years), and those receiving second-line adjunctive therapies in addition to UDCA.29 These 
data are in contrast to stronger correlations reported between APRI and FIB-4 and histologic 
fibrosis stage in other aetiologies of liver disease such as viral hepatitis;  a recent systematic 
review reported an AUROC to detect cirrhosis of 0.84 for APRI and 0.87 for FIB-4 in patients 
with chronic hepatitis C.30 We established disease-specific thresholds for APRI and FIB-4 for 
excluding and including cirrhosis. It is not clear how much utility these will prove to have; only 
a small percentage (7-10%) of the total population met these criteria, emphasizing the 
suboptimal correlation with histologic fibrosis stage.  
Several potential explanations for discordance between liver biopsies and biochemical non-
invasive measures of fibrosis have been reported in the literature and include factors such as 
variability in necro-inflammatory burden across different aetiologies of liver disease, for 
example in HDV/HBV viral co-infection as compared to monoinfection,31 sampling error,32 inter-
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observer variability between pathologists,33 and timing of non-invasive measure assessment 
relative to the time of biopsy.34 Although sampling bias and inter-observer variability could not 
be completely excluded, the large sample size of our cohort can minimize its potential influence 
on our findings. Furthermore, staging was assessed as early and advanced to account for 
interpretive or inter-observer variability, and some of the potentially associated confounding 
factors associated with it, such as center and diagnosis year, which were adjusted for in 
multivariable analyses. Additionally, correlation between histologic stage and biochemical non-
invasive measures of fibrosis is similar when the cohort is limited to biopsies 6 months prior to 
UDCA initiation. 
Our study represents a large cohort of well-characterized patients with PBC, for whom 
histologic staging was available with contemporaneous biochemical variables. Prior studies 
included smaller cohorts with heterogeneous patient populations that may have introduced 
greater bias into evaluations. Despite the size of our study aiding investigation of this rare and 
slowly progressive disease, we wish to have changed aspects were we able to. For example, 
the indications for biopsy were not available and nor were additional histologic variables other 
than fibrosis stage including inflammatory burden, ductopenia and sinusoidal fibrosis, which 
may also be associated with prognosis in PBC. Although biochemical data at baseline were 
not available for all patients due to the real-life nature of the cohort, valid multiple imputation 
methods were implemented to minimize bias. In addition, biopsy data at baseline were only 
available for a subset of patients within the Global PBC Study Group database, although an 
effort was made to consider a potential bias by comparing the patients included in the study to 
those who did not have a biopsy. While those who were biopsied did tend to have higher liver 
tests, they did not have overlap syndrome with autoimmune hepatitis by diagnosis, nor did they 
meet Paris criteria for this, and their survival was comparable to those without a biopsy.  
In conclusion, in evaluating the utility of baseline liver biopsy in patients with PBC, we 
demonstrate that an assessment of fibrosis stage, be it histologically or via non-invasive 
measures of fibrosis, adds meaningful information to individualized patient risk stratification 
beyond biochemical treatment response after 1 year. Whilst liver biopsy is not indicated for 
diagnosis, our data highlights the importance of incorporating available technologies and risk 
stratifiers for liver fibrosis, alongside biochemical markers of cholestatic therapy response, to 
best identify patients at risk of poor outcomes and in need of second-line therapies. 
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Supplementary Table 1. Baseline characteristics of patients with a biopsy that were 
included in the study and those excluded due to a lack of biopsy  
 
 No biopsy 
N=980 
Biopsy at entry 
N=1828 
P value 
Age at study entry, mean (SD) 59.1 (13.0) 52.4 (11.3) <0.001 
Female, n (%) 881 (89.9) 1649 (90.2) 0.79 
UDCA, n (%) 765/926 (82.6) 1828/1828 (100.0) <0.001 
AMA-positive, n (%) 905/966 (93.7) 1586/1761 (90.1) 0.001 
Year of diagnosis, median (P25-75)  2003 (1997-2007) 1998 (1993-2004) <0.001 
Biochemical disease stage†   0.43 
     Mild 458 (72.1) 728 (71.8)  
     Moderately advanced  136 (21.4) 234 (23.1)  
     Advanced 41 (6.5) 52 (5.1)  
Laboratory parameters ‡, median (P25-75)    
     Total bilirubin, ×ULN 0.40 (0.55-0.86) 0.59 (0.43-0.91) 0.01 
     ALP, ×ULN 1.67 (1.08-2.71) 2.12 (1.34-3.83) <0.001 
     Albumin, ×LLN 1.17 (1.06-1.26) 1.16 (1.06-1.26) 0.23 
     AST, ×ULN 1.23 (0.87-1.85) 1.52 (1.06-2.32) <0.001 
     ALT, ×ULN 1.28 (0.77-1.92) 1.72 (1.09-2.70) <0.001 
     Platelet count, ×109/L 240 (184-296) 253 (204-300) 0.01 
Biochemical response at 1 year    
     Toronto 490/723 (67.8) 1165/1781 (65.4) 0.22 
     Paris-II 387/723 (53.5) 953/1781 (53.5) 0.71 
SD, standard deviation; UDCA, ursodeoxycholic acid; AMA, antimitochondrial antibody; ULN, upper limit of 
normal; ALP, alkaline phosphatase; LLN, lower limit of normal, AST, aspartate aminotransferase; ALT, 
alanine aminotransferase.  
 
†Biochemical disease stage according to Rotterdam criteria.14 
‡Laboratory parameters were not available for all patients in the no biopsy group: Total bilirubin (n=745), 
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Supplementary Figure 1. 10-year transplant-free survival estimates of patients with a biopsy 
at baseline and those without a biopsy.  
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Supplementary Table 2. Multivariable Cox regression models that depict the independent 
association of baseline histologic fibrosis stage and non-invasive markers of fibrosis with 
transplant-free survival 
 Multivariable† Multivariable (histologic fibrosis stage) ‡ 
 HR (95% CI) P value  HR (95% CI) P value 
Stage 3/4 2.85 (2.22-3.67) <0.001 - - - 
AAR>1 2.14 (1.65-2.76) <0.001 AAR>1 1.94 (1.48-2.53) <0.001 Stage 3/4 2.66 (2.07-3.42) <0.001 
AAR>0.9§ 1.86 (1.43-2.42) <0.001 AAR>0.9 1.70 (1.30-2.21) <0.001 Stage 3/4 2.70 (2.10-3.47) <0.001 
APRI>2  4.31 (3.01-6.15) <0.001 
APRI>2  3.41 (2.38-4.89) <0.001 
Stage 3/4 2.44 (1.89-3.16) <0.001 
APRI>0.8§ 2.78 (2.13-3.63) <0.001 APRI>0.8 2.35 (1.79-3.09) <0.001 Stage 3/4 2.35 (1.82-3.04) <0.001 
FIB-4>3.25  3.99 (2.87-5.55) <0.001 
FIB-4>3.25 3.16 (2.22-4.52) <0.001 
Stage 3/4 2.27 (1.75-2.95) <0.001 
FIB-4>1.8§ 2.56 (1.93-3.39) <0.001 FIB-4>1.8 2.17(1.63-2.88) <0.001 Stage 3/4 2.47 (1.91-3.19) <0.001 
GLOBE score > 
age-specific 
threshold 
4.60 (3.26-6.49) <0.001 
GLOBE score > 
threshold 
3.93 (2.76-5.58) <0.001 
Stage 3/4 2.08 (1.58-2.74) <0.001 
HR, hazard ratio; CI, confidence interval; AAR, AST to ALT ratio; APRI, AST to platelet ratio index.  
 
†Adjusted for age at the start of follow-up, sex, year of diagnosis, and center.  
‡Adjusted for age at the start of follow-up, sex, year of diagnosis, and center. Baseline histologic fibrosis 
stage (3/4 vs 1/2) was input in a forward selection approach. 
§Threshold derived from our cohort and are based on the highest sensitivity and specificity for the diagnosis 
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Supplementary Table 3. The association of non-invasive biomarkers at baseline and 
response to UDCA at 1 year with transplant-free survival in patients without a biopsy 
  
 
 HR (95% CI) † P value 
Toronto‡   
Non-response 1.99 (1.28-3.11) 0.002 
APRI >0.8 at baseline  2.26 (1.49-3.45) <0.001 
Non-response 2.08 (1.33-3.26) 0.001 
FIB-4>1.8 at baseline 2.22 (1.29-3.83) 0.005 
Non-response 1.96 (1.26-3.04) 0.003 
APRI (LN) at baseline 1.77 (1.39-2.25) <0.001 
Non-response 1.99 (1.27-3.24) 0.003 
FIB-4 (LN) at baseline 2.37 (1.74-3.24) <0.001 
Paris-II§   
Non-response 2.28 (1.38-3.76) 0.001 
APRI >0.8 at baseline  2.03 (1.32-3.14) 0.001 
Non-response 2.44 (1.50-3.97) <0.001 
FIB-4>1.8 at baseline 1.06 (1.21-3.49) 0.008 
Non-response 2.17 (1.32-3.58) 0.003 
APRI (LN) at baseline 1.64 (1.28-2.11) <0.001 
Non-response 2.12 (1.30-3.45) 0.003 
FIB-4 (LN) at baseline  2.20 (1.61-3.00) <0.001 
HR, hazard ratio; CI, confidence interval; APRI, AST to platelet ratio index; LN, natural logarithm.  
†Multivariable model also adjusted for age the start of follow-up, sex, year of diagnosis, and center. 
‡Response defined as ALP≤1.67×ULN. 
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(4) Advanced histologic stage + abnormal ALP
(3) Advanced histologic stage + normal ALP
(2) Early histologic stage + abnormal ALP
(1) Early histologic stage + normal ALP
(1)   471
(2)   720
(3)   139















Supplementary Figure 2. Transplant-free survival estimates after 1 year of treatment with 
ursodeoxycholic acid stratified by baseline histologic fibrosis stage and alkaline phosphatase 
normalization. All pairwise comparisons were significantly different (log-rank: P<0.001), except 


























Early histologic stage Advanced histologic stage
 
Supplementary Figure 3. Distribution of events associated with 10-year survival according to 
biochemical response and histologic fibrosis stage. Percentage of events attributed to liver 
transplantation, liver-related deaths, and liver-related deaths; Chi square: P<0.001 for Toronto 
and Paris-II criteria. 
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Supplementary Table 4. Multivariable Cox regression models that depict the combined 
association of response to treatment after 1 year and baseline fibrosis stage assessed by 
non-invasive markers with transplant-free survival 
 
Group  HR (95% CI) † P value 
Toronto criteria‡   
Response + AAR ≤0.9 1.00  
Non-response + AAR ≤0.9 2.49 (1.67-3.72) <0.001 
Response + AAR >0.9 1.70 (1.15-2.52) 0.008 
Non-response + AAR >0.9 4.79 (3.32-6.90) <0.001 
Response + APRI ≤0.8 1.00  
Non-response + APRI ≤0.8 2.43 (1.58-3.73) <0.001 
Response + APRI >0.8 2.49 (1.67-3.71) <0.001 
Non-response + APRI >0.8 5.34 (3.78-7.52) <0.001 
Response + FIB-4 ≤1.8 1.00  
Non-response + FIB-4 ≤1.8 2.78 (1.86-4.16) <0.001 
Response + FIB-4 >1.8 2.48 (1.61-3.82) <0.001 
Non-response + FIB-4 >1.8 5.56 (3.82-8.10) <0.001 
Paris-II criteria§   
Response + AAR ≤0.9 1.00  
Non-response + AAR ≤0.9 2.78 (1.81-4.26) <0.001 
Response + AAR >0.9 1.29 (0.77-2.14) 0.337 
Non-response + AAR >0.9 5.70 (3.83-8.50) <0.001 
Response + APRI ≤0.8 1.00  
Non-response + APRI ≤0.8 2.29 (1.46-3.60) <0.001 
Response + APRI >0.8 1.33 (0.70-2.51) 0.377 
Non-response + APRI >0.8 5.72 (3.96-8.27) <0.001 
Response + FIB-4 ≤1.8 1.00  
Non-response + FIB-4 ≤ 1.8 2.64 (1.70-4.09) <0.001 
Response + FIB-4 >1.8 1.51 (0.87-2.62) 0.146 
Non-response + FIB-4 >1.8 6.14 (4.10-9.18) <0.001 
HR, hazard ratio; CI, confidence interval, AAR, AST to ALT ratio; APRI, AST to platelet ratio index.  
†Multivariable model also adjusted for age the start of follow-up, sex, year of diagnosis, and center. 
‡Response defined as ALP≤1.67×ULN. 
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Supplementary Table 5. Multivariable Cox regression models that depict the independent 
association of baseline histologic fibrosis stage, and non-invasive fibrosis markers and 
alkaline phosphatase at 1 year with transplant-free survival 
AAR   HR (95% CI) † P value 
AAR at 1 year (LN) 1.18 (1.06-1.31) 0.002 
ALP>1.67 at 1 year 2.39 (1.83-3.14) <0.001 
Baseline histologic fibrosis stage 3/4 2.48 (1.91-3.21) <0.001 
APRI  HR (95% CI) † P value 
APRI at 1 year (LN) 2.69 (2.27-3.19) <0.001 
ALP>1.67 at 1 year 1.47 (1.10-1.97) 0.010 
Baseline histologic fibrosis stage 3/4 1.73 (1.32-2.27) <0.001 
FIB-4 HR (95% CI) † P value 
FIB-4 at 1 year (LN) 3.15 (2.58-3.84) <0.001 
ALP>1.67 at 1 year 1.88 (1.42-2.50) <0.001 
Baseline histologic fibrosis stage 3/4 1.69 (1.28-2.23) <0.001 
AAR, AST/ALT ratio; HR, hazard ratio; CI, confidence interval; ALP, alkaline phosphatase APRI, AST to 
platelet ratio index. 





Supplementary Table 6. The area under the curve for the diagnosis of histologic fibrosis 
stage ≥ 3 and stage = 4 of various biochemical non-invasive markers in the whole cohort and 
sub-group with biopsies 6 months prior to UDCA initiation 
 
  AUROC (95% CI) 
  Overall cohort (n=1828) 6-month biopsies (n=1240) 
Non-invasive marker  Stage ≥ 3 
AAR  0.60 (0.57-0.64) 0.61 (0.57-0.71) 
APRI  0.68 (0.65-0.71) 0.66 (0.62-0.70) 
FIB-4  0.69 (0.67-0.72) 0.68 (0.64-0.71) 
Rotterdam criteria  0.63 (0.61-0.66) 0.62 (0.58-0.66) 
GLOBE score   0.70 (0.67-0.73) 0.69 (0.65-0.72) 
Non-invasive marker  Stage = 4 
AAR  0.63 (0.59-0.67) 0.63 (0.57-0.69) 
APRI  0.69 (0.65-0.72) 0.68 (0.63-0.73) 
FIB-4  0.73 (0.69-0.76) 0.72 (0.67-0.76) 
Rotterdam criteria  0.65 (0.61-0.68) 0.64 (0.58-0.69) 
GLOBE score   0.70 (0.66-0.74) 0.68 (0.63-0.73) 
AUROC, area under receiver operating curve; CI, confidence interval; AAR, AST to ALT ratio; APRI, AST to 
platelet ratio index.  
 
 




Supplementary Figure 4. Transplant-free survival estimates after 1 year of treatment with 
ursodeoxycholic acid stratified by baseline histologic fibrosis stage and biochemical response 
according to A) Toronto criteria and B) Paris-II criteria. Patients included had biopsies up to 6 
months before, but not after UDCA initiation. All pairwise comparisons were significantly 
different (P<0.01), except that of early histologic stage + non-responder vs. advanced 







Supplementary Table 7. The performance of high and low cut-offs of non-invasive markers 
of fibrosis for the exclusion and inclusion of cirrhosis  
 
 Low cut-offs (‘rule out’ cirrhosis) 
 Frequency Sensitivity NPV Specificity PPV 
Conventional      
    APRI≤1.0 1336 (73.1%) 48.9 87.9 77.7 31.4 
    FIB-4≤1.45† 917 (50.1%) 75.0 91.4 55.4 26.0 
Global PBC      
    APRI≤0.26 172 (9.4%) 95.3 91.3 10.4 18.2 
    FIB-4≤0.70 186 (10.2%) 95.2 91.8 11.3 18.3 
 High cut-offs (‘rule in’ cirrhosis) 
 Frequency Sensitivity NPV Specificity PPV 
Conventional        
    APRI>2.0 145 (7.9%) 21.2 85.2 94.9 46.4 
    FIB-4>3.25† 226 (12.3%) 33.1 86.8 92.0 46.4 
Global PBC      
    APRI>2.0 145 (7.9%) 21.2 85.2 94.9 46.4 
    FIB-4>4.03 150 (8.2%) 23.1 85.5 94.9 48.7 
NPV, negative predictive value; PPV, positive predictive value; APRI, AST to platelet ratio index.  
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Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that predominantly 
affects 1 in 1000 women over the age of 40. Due its relative rarity and slow progression to 
clinical events, studying this disease in a robust manner would require inclusion of a large 
number of patients with long-term follow-up, which can be difficult from single-center studies. 
Thus, a culmination of patient data from multiple centers and in an international manner can 
be greatly informative and aid in the generalizability of findings. Such efforts have been 
achieved with national and international groups such as the UK-PBC Consortium, CaNAL, and 
as evaluated in this thesis, the Global PBC Study Group. Importantly, the predictive ability of 
main liver biomarkers, alkaline phosphatase (ALP) and bilirubin, as surrogate end points for 
clinical outcomes in PBC patients was studied in the Global PBC Study group database.1 
These are now widely used in clinical practice and clinical trials, both to determine the need 
for second-line therapies and to evaluate the efficacy of treatment. Ultimately, the goal is to 
optimize patients’ prognosis through guidance of patient management, which can be 
accomplished with care pathways, identification of risk factors, determination of the need of 
second-line therapies, and establishment of biochemical treatment targets. 
Temporal and Spatial Trends in PBC  
There have been multiple studies evaluating temporal trends for PBC, particularly with regards 
to its incidence and prevalence. A systematic review demonstrated that the prevalence for 
PBC has increased over time.2 The pattern for incidence over time differs between studies, as 
some reported increased incidence and others stability.3,4 Yet, seldom have patient 
characteristics and clinical outcomes of patients been described temporally. A single-center 
study from Padova, Italy suggested that the mean age at diagnosis increased from 48 years 
in patients diagnosed in 1973 to 64 years in those diagnosed in 2007.5 Similarly, in a Japanese 
population, the median age at diagnosis increased from 59 year in 1999 to 63 years in 2004.6 
A Canadian population-based study of patients diagnosed from 1996 through 2002 did not 
report a significant difference in survival according to year of diagnosis.7 Chapter 2 evaluated 
the changes in patient characteristics and clinical outcomes of patients with PBC from a 
globally representative cohort over a 44-year period according to decades. The mean age at 
diagnosis increased by 2-3 years per decade from 47 years in the 1970s to 57 years beyond 
2010. Furthermore, at presentation, patients were of a reduced disease severity in recent 
decades, as indicated by biochemical disease stage, histology, and ALP and bilirubin levels. 
The incidence of decompensation decreased over time and improvements in 10-year 
transplant-free survival were noted. These findings demonstrate how the patient population 
has evidently changed over time. Independent of whether this is due to an aging population, a 




changing environmental trigger, increased disease awareness, increased routine testing of 
liver function, the introduction of ursodeoxycholic acid (UDCA), or a combination thereof, it 
highlights that PBC has not been a static disease. Given that the introduction of UDCA in the 
1990s likely played a role in the improvement in survival, novel second-line therapies for those 
who do not respond to UDCA are still needed.8 There is the possibility for continued changes 
in the patient population as a result of greater improvements in patient management and the 
introduction of novel second-line therapies such as obeticholic acid (OCA), which is currently 
being studied in relation to its effect on clinical outcomes (COBALT). 
Like calendar time trends, those according to geographical region have primarily focused on 
incidence and prevalence. Different regions have varying incidence and prevalence of PBC, 
with some of the highest reported in Northeast England, Iceland, Calgary, and Minnesota.7,9–
11 In Chapter 3, the patient characteristics and clinical outcomes of patients from the European 
centers in the Global PBC database (Western Europe) were assessed according to 
geographical region. There were differences in decompensation and transplant-free survival 
according to region, albeit no differences in patient age and sex were noted. Increased hepatic 
decompensation rates and decreased transplant-free survival were observed for the 
Northwestern region evaluated, pertaining to the United Kingdom, even when adjusting for 
various markers of disease severity. Even though the contributing factors for the varying rates 
in clinical outcomes are not clear at this time, it raises the possibility that an environmental 
factor is at play. Understanding and acknowledging differences in patient outcomes within 
Europe and beyond can highlight at-risk populations based on region.   
Risk Stratification  
Some of the common factors that drive risk stratification in PBC are demographic factors and 
liver biochemistry.12–18 Demographic factors such as age and sex have been found to be 
associated with prognosis. Male sex has been identified as a risk factor for incomplete 
response to UDCA, irrespective of age, portal hypertension, and biochemical indices of 
disease severity19, and male patients appear to have diminished transplant-free survival 
compared to females.7,20 On the other hand, increasing age is associated with increased 
response to UDCA, notably in female patients.19 Chapter 4 assessed the impact of age and 
sex on response to UDCA and clinical outcomes. The prognostic value of age on response to 
UDCA and transplant-free survival was validated as an increased age was associated with 
increased likelihood of response, while the risk for liver transplant or death decreased with 
advanced age when compared to a general population matched for age, sex, and birth year. 
In contrast, male sex was not associated with response nor survival in multivariable analysis. 
These results emphasize that younger patients ought to be monitored closely as they appear 
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to be at greater risk for incomplete response to UDCA, liver transplantation, and death. Indeed, 
the influence of age on response has been underlined in the UDCA Response Score, which is 
applied at baseline to predict the probability of response at 1 year to consider the need for 
second-line therapies in a timely manner.21 Age is also included in the GLOBE score to predict 
transplant-free survival.12 On the contrary, the worse prognosis of males can be explained by 
the fact that they are diagnosed at a more advanced disease stage, indicated by higher bilirubin 
and the greater proportion with moderately advanced and advanced biochemical stage. This 
is potentially due to delays in diagnosis given that they represent the minority of the affected 
population. Therefore, it is important to maintain high vigilance for a timely diagnosis in male 
patients with PBC.    
Fibrosis stage is a well-established risk factor in PBC as an advanced histologic stage is 
associated with an increased risk for liver transplantation or death.5,14 However, risk 
stratification assessed by published response criteria largely rely on biochemical markers and 
do not consider fibrosis stage. In Chapter 5, the utility of baseline fibrosis stage in determining 
transplant-free survival in the context of response to UDCA was evaluated. The correlations 
between non-invasive biochemical markers and histologic stage were poor. Advanced fibrosis 
stage at baseline, assessed histologically and via non-invasive biochemical markers, granted 
additional prognostic value to response to UDCA at 1 year. Despite biochemical response at 
1 year, those with an advanced histologic stage have diminished transplant-free survival 
compared to those with an early fibrosis stage. This study highlights the need to incorporate 
fibrosis stage in patient risk stratification to identify the need for second-line therapies in 
addition to biochemical markers. Implementation can select a subgroup of patients who 
otherwise may not have been candidates for second-line therapies based on biochemistry 
alone. Yet, whether novel second-line therapies may benefit these patients remains to be 
studied. Importantly, there is a need to establish reliable non-invasive measures of fibrosis. 
Liver biopsies can aid in staging of disease, but they are not essential for a diagnosis of PBC. 
A promising approach to assess liver fibrosis is measuring liver stiffness by transient 
elastography, which demonstrates strong correlations with fibrosis stage.22 The timing of 
elastography as a surrogate, be it at baseline or 1 year, needs further consideration due to the 
combined effect of fibrosis and cholestasis on liver stiffness.  
Multiple risk scores that can predict the risk for clinical outcomes have been proposed over the 
years. Earlier risk scores include the Mayo Risk Score 1994 (MRS) and Model for End-stage 
Liver Disease (MELD) score, which were developed to predict short-term survival at 2 years 
and 3 months, respectively.23,24 The more recent GLOBE and UK-PBC scores predict 
transplant-free survival and liver transplantation and liver-related death, respectively.12,13 
Chapter 6 compared the performance of risk scores developed to predict outcome in PBC 




(MRS, UK-PBC, and GLOBE score) in a UDCA-treated population. The GLOBE score was 
found to have consistently better performance in discriminatory ability for the prediction of liver 
transplantation and death in comparison to the remaining risk scores at various time points. 
However, this was not statististically different in comparison to the other scores. Importantly, 
the population was of a predominantly early biochemical disease stage, a population that 
represents the majority of patients in recent decades (Chapter 1). Therefore, implementation 
of risk scores in PBC should be based on clinical context.  
Recently developed risk scores include similar risk factors in the model to predict survival, 
which are mainly liver biochemistry (ALP, bilirubin, albumin, platelet count, transaminases) and 
age. An improvement of these risk scores may be possible by considering additional variables 
that are associated with survival. Novel prognostic factors that are being increasingly evaluated 
are autoantibodies. Antinuclear antibodies (ANAs) are associated with disease severity and 
prognosis, as patients who are positive for these autoantibodies tend to have more severe 
biochemical and histological disease.25 Anti-gp210 is associated with marked cholestasis and 
impaired liver function, as well as more severe interface hepatitis and lobular inflammation.26–
29 A meta-analysis that evaluated the prognostic value of anti-gp210 reported an association 
between anti-gp210 positivity and progression to liver failure and mortality.30 Another 
prognostic factor that may be beneficial is neutrophil-to-lymphocyte ratio (NLR), for which a 
high NLR above 2.46 has been associated with reduced transplant-free survival in a Korean 
population.31 Further research is required to establish the association between these 
prognostic factors and survival, but emphasize that efforts ought to be made to include other 
variables beyond demographics and liver biochemistry to obtain a more accurate and complete 
prediction model for clinical outcomes in patients with PBC. 
Management of Patients 
There are various risk stratification tools available for patients with PBC, both continuous risk 
scores and binary response criteria.12–18 These have greatest value and applicability in 
specialized centers for PBC, as these may be confusing for non-specialist clinicians due to 
their complexity and abundance of options. It is important that there be the opportunity to 
highlight early in the course of disease those who should be offered enhanced care 
(programmes with focused PBC-experienced physicians), which can be achieved with care 
pathways. There is lack of a simple and rapid risk assessment tool to guide care pathways at 
diagnosis and assist non-expert gastroenterologists and primary care providers with the 
decision for referral. As demonstrated from previous research and in Chapter 4, increasing 
age is associated with an increased likelihood of response to UDCA and a smaller deviation 
from the survival of a general population. Age has not been consistently included in all risk 
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stratification tools, albeit present in the GLOBE score and UDCA Response Score.12,21 In 
Chapter 7, a simple risk algorithm that captures age and serum liver tests was developed to 
guide care pathways. The ABA risk tool was proposed, which include age, bilirubin, and ALP, 
to three risk groups: low (Age>50 years, bilirubin ≤1×ULN, alkaline phosphatase [ALP] 
≤3×ULN), high (Age≤50 years, bilirubin >1×ULN, ALP >3×ULN), and intermediate (other 
combinations). High risk patients were proposed to enhanced care and the remaining 
reassessed at 1 year, for which those in the intermediate and high risk were proposed to 
enhanced care. As an extension of the results from Chapter 5, fibrosis stage was assessed in 
those proposed to standard care (primary care) after 1 year, which was found to provide 
additional prognostic value. Overall, it was demonstrated that implementing a simple clinical 
risk tool in PBC in non-expert settings can promptly provide patients with augmented care if 
deemed necessary. While consideration of fibrosis stage is still important and to date transient 
elastography has been strongly correlated with fibrosis stage, it is not universally available 
across primary care settings. This could therefore hinder its use outside a liver care setting, 
particularly since the sole reliance on non-invasive biochemical markers such as APRI or FIB-
4 is not optimal due to their poor correlation with fibrosis stage in PBC (Chapter 5). The 
takeaway message is that while ABA may not be determined as the optimal tool, it can be used 
as a basis to develop a simple, yet efficient care pathway in PBC. 
Bilirubin is an established risk factor for PBC in treated and untreated patients.1,32,33 It was first 
found to be associated with prognosis in untreated patients, in which a sharp increase in 
bilirubin preceded death.32 Inclusion of bilirubin in various prognostic models and response 
criteria highlights its importance. Yet, bilirubin is thought to be of limited value early in the 
course of disease due to the fact that elevations are not observed until later stages of the 
disease.34 A previous study by the Global PBC Study group assessed ALP and bilirubin as 
surrogate end points for clinical outcomes.35 While this study determined normal bilirubin to be 
the optimal threshold, thresholds below the upper limit of normal were not evaluated. The 
majority of patients who are included in clinical trials have normal bilirubin, as demonstrated in 
the Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE) trial, 
for which 6-10% of patients had abnormal bilirubin.36 Further, even within the normal range, 
patients experienced reductions in bilirubin. Whether bilirubin within the normal range or 
reductions in bilirubin were associated with clinical outcomes in PBC was unclear. In Chapter 
8, the association between normal bilirubin and reductions within the normal range were 
examined, along with the predictive value of ALP below a threshold of 1.67×ULN. In this study, 
the treatment targets for ALP and bilirubin, which are main liver biomarkers in clinical trials, 
were redefined. A threshold of 0.6×ULN for bilirubin and ALP normalization were found to be 
optimal. Below 0.6×ULN of bilirubin, the lowest risk for liver transplantation or death is 




observed, after which there is a linear increase in risk. A UDCA-induced reduction in bilirubin 
below this threshold at 1 year was also associated with improvements in transplant-free 
survival. As a result, implementing these thresholds can broaden the patient criteria for whom 
second-line therapies may be considered, as well as redefine treatment targets to optimize 
patient survival. While this study only focused on the main biomarkers of PBC, it is plausible 
that a similar association may be observed for additional liver biochemistry, which remains to 
be studied.  
CONCLUSIONS  
This thesis contributes a range of knowledge to the existing literature in PBC. Over the years, 
the patient characteristics and outcomes of patients with PBC has changed, characterized by 
an increase in age at diagnosis, milder disease stage, and improved clinical outcomes. It is 
plausible that geographical region may have an impact on clinical outcomes of PBC, 
particularly in the UK region within Western Europe. Age is an independent predictor for 
response to UDCA and transplant-free survival, while male patients tend to present with more 
advanced disease stage at baseline. Fibrosis stage is an important risk factor to consider in 
addition to biochemical response when risk stratifying patients, as those with biochemical 
response but advanced fibrosis have worse transplant-free survival. When comparing the 
various risk scores in PBC, the MRS, UK-PBC and GLOBE scores are comparable in the 
prediction of liver transplantation and death. In non-expert settings, the proposal of patients 
early in the course of disease to a care pathway and determination of the need for referral can 
be communicated with a simple risk assessment tool that requires fibrosis stage to be 
incorporated in future iterations. Bilirubin within the normal range and ALP normalization are 
associated with improved transplant-free survival. This suggests more patients ought to be 
treated to optimize survival and warrants a refinement of treatment biochemical targets.  
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Primaire biliaire cholangitis (PBC) is een chronische, cholestatische leverziekte waarbij 
voornamelijk vrouwen zijn aangedaan; 1 op de 1000 vrouwen boven de 40 jaar heeft deze 
ziekte. Robuust onderzoek naar deze ziekte is lastig, omdat het relatief zeldzaam is en het 
beloop tot het eindstadium van de leverziekte of het overlijden aan de ziekte een langzaam 
progressief beloop kent. Om kwalitatief goed onderzoek te verrichten zijn grote 
patiëntengroepen nodig met een jarenlange follow-up duur en dit is nauwelijks te realiseren 
vanuit één onderzoekscentrum. Daarom is een samenwerking tussen multiple centra 
wereldwijd noodzakelijk en dit heeft als extra voordeel dat de resultaten beter generaliseerbaar 
zijn. Naast de Global PBC Study Group, waarvan meerdere studies opgenomen zijn in dit 
proefschrift, hebben meerdere samenwerkingsverbanden, zoals de UK-PBC Consortium en 
CaNAL, zichzelf reeds bewezen. De Global PBC Study Group richtte zich in eerste instantie 
op het valideren van biomarkers, zoals alkalische fosfatase (ALP) en bilirubine, als surrogaat 
voor klinische eindpunten in PBC patiënten.1 Deze worden nu wereldwijd gebruikt in de 
klinische praktijk en in klinische trials waarbij de noodzaak voor tweedelijnsbehandeling wordt 
onderzocht, alsmede de effectiviteit van potentiële medicatie. Het uiteindelijke doel van 
internationale samenwerkingsverbanden is om de prognose van PBC patiënten te 
optimaliseren met behulp van heldere behandelstrategieën, door het opstellen van zorgpaden, 
het identificeren van risicofactoren, het vroegtijdig inzetten van tweedelijnsbehandelingen en 
het vaststellen van biochemische behandeldoelen.  
Trends in tijd en plaats   
Er zijn meerdere studies die trends over de tijd hebben beschreven, met name met betrekking 
tot incidentie en prevalentie. Zo toonde een systemische review aan dat de prevalentie van 
PBC is toegenomen over de tijd.2 De incidentiecijfers over de tijd verschillen tussen studies, 
waarbij sommige studies stabiele cijfers beschrijven en anderen een toename.3,4 Verschillen 
in karakteristieken en klinische uitkomsten van PBC patiënten over de tijd zijn echter 
sporadisch beschreven. Een studie uit Padova in Italië suggereert dat de gemiddelde leeftijd 
waarop de ziekte PBC wordt vastgesteld, is toegenomen van 48 jaar in 1973 tot 64 jaar in 
2007.5 Een Japanse studie laat een vergelijkbaar resultaat zijn, waarbij de gemiddelde leeftijd 
bij diagnose toenam van 59 jaar in 1999 tot 63 jaar in 2004.6 Een Canadese population-based 
studie van patiënten gediagnosticeerd tussen 1996 en 2002 liet geen verschillen in overleving 
zien tussen de verschillende diagnosejaren.7 Hoofdstuk 2 toont de resultaten van een 
internationale studie die de trends in patiëntkarakteristieken en klinische uitkomsten van PBC 
patiënten beschrijft over een periode van 44 jaar. De gemiddelde leeftijd bij diagnose nam toe 
van 47 jaar in 1970 tot 57 jaar in 2010; een toename van 2-3 jaar per decade. Bovendien bleek 




dat patiënten over de tijd in een eerder biochemisch of histologisch ziektestadium worden 
gediagnosticeerd. Ook de incidentie van gedecompenseerde leverziekte daalde en de 10-jaar 
transplantatievrije overleving verbeterde over de tijd. De resultaten laten duidelijk zien hoe de 
patiëntenpopulatie is veranderd en dat PBC geen statische ziekte is, onafhankelijk of dit wordt 
veroorzaakt door een ouder wordende populatie, verandering in omgevingsfactoren, meer 
bewustzijn voor de ziekte, de introductie van ursodeoxycholzuur (UDCA), of een combinatie 
van deze factoren. De introductie van UDCA in de jaren ’90 heeft bijgedragen aan de 
verbetering van de overleving van het grootste deel van de PBC patiënten en daarom zijn 
tweedelijnsbehandelingen noodzakelijk voor degenen die niet adequaat op dit medicijn 
reageren.8 Waarschijnlijk zal de patiëntenpopulatie ook in de toekomst blijven veranderen als 
een gevolg van verbeteringen in de behandeling van patiënten en de introductie van een 
tweedelijnsbehandeling, zoals obeticholzuur (OCA), waarvan het effect op klinische 
uitkomsten op dit moment wordt onderzocht in de COBALT studie.  
Ook studies die zich richtten op het beschrijven van trends in een bepaalde geografisch 
gebied, focusten zich met name op incidentie- en prevalentiecijfers. Het blijkt dat er een 
duidelijke variatie is tussen regio’s, waarbij de hoogste aantallen werden geobserveerd in 
Noordoost-Engeland, IJsland, Calgary en Minnesota.7,9-11 In hoofdstuk 3 worden de 
resultaten beschreven van een studie die verschillen in patiëntkarakteristieken en klinische 
uitkomsten heeft onderzocht tussen PBC patiënten uit verschillende West-Europese regio’s. 
Ondanks dat er geen leefijds- en geslachtsverschillen waren tussen de diverse gebieden, 
werden er wel verschillen gevonden in de mate van decompensatie en transplantatievrije 
overleving. In het Noordwesten van het Verenigde Koninkrijk werd een hoger percentage 
gedecompenseerde leverziekte en een afgenomen transplantatievrije overleving gevonden, 
onafhankelijk van de verschillen in ernst van de ziekte tussen de regio’s. Desondanks is het 
niet met zekerheid te zeggen welke factoren werkelijk bijdragen aan de regionale verschillen 
in klinische uitkomsten; mogelijk spelen omgevingsfactoren een belangrijke rol. Begrip van 
deze factoren kan bijdragen aan het bepalen van risicogroepen op basis van regio.  
Risicostratificatie 
Demografie en biochemie zijn belangrijke factoren waarmee het risico van PBC patiënten kan 
worden gestratificeerd.12-18 Bekende demografische factoren, zoals leeftijd en geslacht, zijn 
geassocieerd met prognose. Zo is het mannelijke geslacht een risicofactor voor een 
incomplete respons op UDCA, onafhankelijk van de leeftijd, de aanwezigheid van portale 
hypertensie, en de ernst van de ziekte op basis van biochemische variabelen.19 Eveneens 
hebben mannelijke PBC patiënten een lagere transplantatievrije overleving dan vrouwen.7,20 
Aan de andere kant is een hogere leeftijd geassocieerd met een verhoogde respons op UDCA 
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en dit geldt met name voor vrouwelijke patiënten.19 In hoofdstuk 4 komt de impact van leeftijd 
en geslacht op de UDCA respons en klinische uitkomsten aan bod. De prognostische waarde 
van leeftijd op UDCA respons en klinische uitkomsten werd gevalideerd; een hogere leeftijd 
was geassocieerd met een betere respons op UDCA, terwijl het overlijdensrisico juist lager 
was in vergelijking met de overleving van een algemene populatie (met een vergelijkbare 
verdeling van leeftijd, geslacht en geboortejaar). In tegenstelling hieraan werd er in een 
multivariabele analyse geen verschil gevonden tussen mannelijke en vrouwelijke PBC 
patiënten betreffende UDCA respons of transplantatievrije overleving. Deze resultaten 
onderstrepen dat jonge PBC patiënten strikter moeten worden gecontroleerd, omdat ze 
gemiddeld genomen minder goed reageren op behandeling met UDCA en een hoger risico 
hebben op leverfalen en dus de noodzaak voor een levertransplantatie of overlijden. Deze 
bevindingen zijn in lijn met de UDCA Response Score, die bij het starten met de UDCA 
behandeling voorspelt hoe groot de kans is op een respons na 1 jaar behandeling, om zo tijdig 
te kunnen ingrijpen met tweedelijnsbehandeling.21 De variabele ‘leeftijd’ is ook onderdeel van 
de GLOBE score; een score die de transplantatievrije overleving in PBC patiënten voorspelt.21 
De matige prognose van mannelijke PBC patiënten wordt met name verklaard door het feit dat 
zij zich bij diagnose in een verder gevorderd ziektestadium bevinden (op basis van 
biochemische variabelen) dan vrouwen. Vermoedelijk komt dit doordat het proces van 
diagnosestelling langer duurt, omdat PBC nu éénmaal veel minder voorkomt bij mannen dan 
bij vrouwen. Het is dus belangrijk om waakzaam te blijven om zodoende op tijd de diagnose 
PBC bij een mannelijke patiënt te kunnen stellen.  
Het stadium van fibrose is een belangrijke risicofactor in PBC, waarbij patiënten met een verder 
gevorderd ziektestadium op basis van histologie een lagere transplantatievrije overleving 
hebben.5,14 Echter, risicostratificatie op basis van respons criteria is voornamelijk gebaseerd 
op biochemie en niet op histologie. In hoofdstuk 5 werd geëvalueerd welke waarde het 
fibrosestadium heeft in het voorspellen van de transplantatievrije overleving van PBC patiënten 
in de context van respons op behandeling met UDCA. Er bleek een slechte correlatie te zijn 
tussen niet-invasieve biochemische waarden en het histologische stadium. Toegenomen 
fibrosestadium op basis van histologie en biochemie had additionele voorspellende waarde 
ten aanzien van biochemische respons op UDCA na 1 jaar behandeling. Het bleek namelijk 
dat responders op UDCA en een gevorderd histologische ziektestadium een minder goede 
transplantatievrije overleving hadden dan patiënten in een vroeg stadium van fibrose. Deze 
studie onderstreept het belang van het fibrosestadium in additie op biochemie bij het 
stratificeren van risico om patiënten te identificeren die in aanmerking komen voor 
tweedelijnsbehandeling. Zodoende kan een groep worden geïdentificeerd die alleen op basis 
van biochemie niet in aanmerking zou zijn gekomen voor tweedelijnsbehandeling. Of deze 




patiënten baat zullen hebben bij tweedelijnsbehandeling moet nog worden onderzocht. Er is 
een duidelijke noodzaak voor niet-invasieve markers voor fibrose, omdat histologie niet meer 
nodig is voor het stellen van de diagnose PBC. Een veelbelovende aanpak om leverfibrose te 
meten is met behulp van de fibroscan, waarbij er eerder een sterke corelatie met het 
fibrosestadium is aangetoond.22 Wanneer de fibroscan moet worden ingezet als surrogaat voor 
het fibrosestadium, het zij bij het stellen van de diagnose of na één jaar behandeling met 
UDCA, dient nog te worden onderzocht, mede gezien het feit dat de aanwezigheid van 
cholestase de uitslagen van de fibroscan negatief beïnvloed.  
Er zijn veel risicoscores ontwikkeld over de jaren die klinische uitkomsten voorspellen voor 
PBC patiënten (MRS, UK-PBC en GLOBE). In hoofdstuk 6 worden de resultaten weergeven 
van een studie die het voorspellend vermogen van deze risicoscores vergelijkt in UDCA-
behandelde PBC patiënten. De GLOBE score had consequent betere prestaties in 
discrimininerende vermogen voor de voorspellen van levertransplantatie en overlijden in 
vergelijking met de resterende risicoscores op diverse punten in de tijd. Echter, dit was niet 
statistisch anders in vergelijking met de andere scores. Hierbij is het van belang dat het 
grootste deel van de onderzochte populatie PBC patiënten waren in een vroeg biochemisch 
ziektestadium; een populatie representatief voor de huidige groep PBC patiënten (zie 
hoofdstuk 1). Daarom moet de implementatie van risicoscores in PBC gebaseerd zijn op 
klinische context. 
Recent ontwikkelde risicoscores maken gebruik van vergelijkbare variabelen in het model 
voornamelijk bestaande uit leverbiochemie (alkalische fosfatase, bilirubine, albumine, 
trombocyten en transaminasen) en leeftijd. Om deze scores te optimaliseren kan overwogen 
worden om niet-biochemische variabelen toe te voegen die geassocieerd zijn met overleving. 
Tegenwoordig is er veel belangstelling voor autoantilichamen. Antinucleaire antilichamen 
(ANA’s) zijn geassocieerd met de ernst van de ziekte en met prognose, aangezien patiënten 
positief voor deze autoantilichamen ernstigere leverziekte hebben op basis van biochemie en 
histologie.25 Anti-gp210 is geassocieerd met uitgesproken cholestase, verminderde 
leverfunctie, ernstigere interface hepatitis en lobulaire inflammatie.26-29 Een meta-analyse die 
de prognostische waarde van anti-gp210 evalueerde, rapporteerde een associatie tussen de 
aanwezigheid van anti-gp210 en progressie van leverfalen en mortaliteit.30 Een andere 
prognostische factor is de neutrofiel-lymfocyt ratio (NLR), waarbij een NLR boven de 2.46 
geassocieerd is met een verminderde transplantatievrije overleving in een Koreaanse 
populatie.31 Verder onderzoek is nodig om de associatie te onderzoeken tussen deze 
prognostische factoren en overleving. Ze maken wel duidelijk dat andere variabelen dan de 
bekende demografische en biochemische variabelen mogelijk een accuratere voorspelling 
kunnen geven van klinische uitkomsten in PBC patiënten.  
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Behandeling van PBC patiënten 
Er zijn verschillende middelen beschikbaar voor risicostratificatie in PBC patiënten, waaronder 
binaire- en continue responscriteria.12-18 Deze hebben een grote waarde voor de praktijk en ze 
worden toegepast in gespecialiseerde PBC centra. Echter, voor artsen die PBC patiënten 
behandelen in minder gespecialiseerde ziekenhuizen kunnen deze modellen te complex en 
uitgebreid zijn. Het is van belang om vroegtijdig in het beloop van de ziekte patiënten te 
selecteren die verwezen dienen te worden voor gespecialiseerde zorg en hiervoor zouden 
zorgpaden kunnen worden gebruikt. Daarom zou een simpel en snel te berekenen score 
behulpzaam kunnen zijn, echter zo’n score is op dit moment niet beschikbaar. Zoals reeds 
beschreven in hoofdstuk 4 en gedemonstreerd door andere studies, is een hogere leeftijd 
geassocieerd met een toegenomen kans op UDCA respons en een overleving die dichter bij 
die van een algemene bevolking ligt dan van jonge PBC patiënten. Op dit moment is leeftijd 
alleen geïncludeerd in de GLOBE score en de UDCA Response Score.12,21 In hoofdstuk 7 
wordt een simpel algoritme (ABA score) gepresenteerd inclusief leeftijd en biochemie. Deze 
score onderscheid 3 risicogroepen: laag risico (leeftijd >50 jaar, bilirubine ≤1xULN, alkalische 
fosfatase ≤3xULN), hoog risico (leeftijd ≤50 jaar, bilirubine >1xULN en ALP>3xULN) en 
gemiddeld risico (andere combinaties van leeftijd, bilirubine en alkalische fosfatase). Op basis 
van de resultaten van hoofdstuk 5 werd de toegevoegde waarde van fibrosestadium na 1 jaar 
behandeling met UDCA geanalyseerd in de laagrisico groep en dit bleek het geval te zijn. In 
het algemeen werd met deze studie aangetoond dat implementatie van deze ABA-score in 
niet-in-PBC-gespecialiseerde ziekenhuizen patiënten kan selecteren die meer 
gespecialiseerde zorg nodig hebben. Ondanks dat de aanvullende waarde van het 
fibrosestadium bewezen is en de fibroscan een goede niet-invasief medium is om fibrose vast 
te stellen, is deze fibroscan niet altijd beschikbaar. Helaas hebben andere niet-invasieve 
factoren, zoals de APRI of FIB-4 scores, geen sterke associatie met de aan- of afwezigheid 
van fibrose in PBC patiënten (hoofdstuk 5). Ondanks dat de ABA score hierdoor niet optimaal 
is, kan deze score de basis vormen voor de ontwikkeling van een simpel en efficiënt zorgpad 
in PBC.  
Bilirubinewaarden zijn geassocieerd met prognose in onbehandelde en behandelde PBC 
patiënten.1,32,33 In eerste instantie werd deze associatie beschreven bij onbehandelde 
patiënten, waarbij een sterke stijging in bilirubinewaardes  voorafging aan het overlijden van 
PBC patiënten.32 Het is niet voor niets dat bilirubine geïncorporeerd is in multipele 
predictiemodellen. Bilirubine heeft echter voornamelijk belangrijk prognostische betekenis bij 
gevorderde leverziekte, omdat de bilirubinewaardes pas laat in het ziekteproces stijgen.34 Een 
eerdere studie van de Global PBC Study Group onderzocht reeds de waarde van alkalische 
fosfatase en bilirubine als surrogaten voor klinische eindpunten.35 Ondanks dat deze studie 




normale bilirubinewaardes als optimaal beschouwde, werd de prognostische betekenis van 
bilirubinewaarden onder de bovengrens van normaal niet onderzocht. Tegenwoordig heeft het 
merendeel van de patiënten in klinische studies normale bilirubinewaarden, zoals 
gedemonstreerd in de fase 3 studie voor obeticholzuur in PBC (POISE trial), waar slechts 6-
10% een abnormale bilirubinelevel had.36 Patiënten in deze studie lieten een daling van het 
bilirubine zien binnen de grenzen van normaal. Het is echter onduidelijk of deze daling zich 
ook daadwerkelijk laat vertalen in verbeterde transplantatievrije overleving. In hoofdstuk 8 
werd de associatie tussen normale bilirubinewaardes en een reductie binnen de 
normaalwaarden onderzocht, alsmede de predictieve waarde van alkalische fosfatase 
waarden onder de 1.67xULN. In deze studie werden nieuwe behandeldoelen op basis van 
alkalische fosfatase en bilirubine vastgesteld; de belangrijkste biochemische variabelen die 
gebruikt worden in klinische studies. Geconcludeerd werd dat de meest optimale 
afkapwaarden voor bilirubine en alkalische fosfatase 0.6xULN en 1.0xULN respectievelijk 
waren. Patiënten met bilirubinewaarden onder de 0.6xULN hebben het laagste risico op de 
noodzaak voor een levertransplantatie of overlijden en het risico neemt lineair toe met 
stijgende bilirubinewaarden. Een reductie van bilirubinewaarden onder deze afkapwaarde na 
1 jaar behandeling met UDCA was ook geassocieerd met een verbeterde transplantatievrije 
overleving. Op basis van deze resultaten zouden huidige behandeldoelen moeten worden 
bijgesteld, zodat de overleving van PBC patiënten wordt geoptimaliseerd. Deze studie richtte 
zich op de belangrijkste leverwaarden, alkalische fosfatase en bilirubine; het is goed mogelijk 
dat andere leverbiochemie een vergelijkbare trend laat zien. Om dit aan te tonen zijn verdere 
studies noodzakelijk.  
Conclusies 
Dit proefschrift voegt relevante kennis toe aan de bestaande literatuur over PBC. Door de tijd 
heen zijn de karakteristieken van PBC patiënten alsmede de prognose veranderd en dit wordt 
geïllustreerd door een toename van de leeftijd bij de diagnosestelling, een mildere ziekte en 
een verbetering van klinische uitkomsten door de jaren heen. Het is aannemelijk dat 
geografische verschillen een invloed hebben op de klinische uitkomsten in PBC, met name in 
het Verenigde Koninkrijk ten opzicht van de rest van West-Europa. Leeftijd is een belangrijke 
onafhankelijke voorspeller voor de respons op UDCA en voor de transplantatievrije overleving, 
terwijl mannen zich voornamelijk presenteren met een verder gevorderd ziektestadium ten tijde 
van de diagnosestelling. Wanneer het gaat om risicostratificatie is het fibrosestadium van 
toegevoegde waarde op biochemische respons op UDCA en dit wordt onderstreept door de 
bevinding dat PBC patiënten met een respons op UDCA en een toegenomen fibrosestadium 
een slechtere transplantatievrije overleving hebben. MRS, UK-PBC en GLOBE risicoscores 
had vergelijkbaar prestaties in discrimininerende vermogen voor de voorspellen van 
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levertransplantatie en overlijden. In ziekenhuizen zonder PBC-experts kan er gebruik worden 
gemaakt van een makkelijke score (ABA-score) om onderscheid te maken tussen patiënten 
die vervolgens in een zorgpad kunnen worden behandeld, of patiënten die naar een 
expertcentrum moeten worden verwezen. In de toekomst zal moeten worden onderzocht hoe 
het fibrosestadium in deze score kan worden geïmplementeerd. Bilirubine binnen de 
normaalwaarden en normalisatie van alkalische fosfatase zijn geassocieerd met een 
verbeterde transplantatievrije overleving. Deze bevinding suggereert dat er meer PBC 
patiënten zijn die baat kunnen hebben bij tweedelijnsbehandeling en dat huidige 
behandeldoelen moeten worden bijgesteld.  
 
A special thank you to Wim Lammers for helping translate this summary    
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